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ABSTRACT 
Study Purpose:  Ovarian cancer, the most lethal gynecologic cancer, has had a relatively stable 
mortality rate since 1975, despite a decrease in mortality for all gynecologic cancers combined. 
Standard-of-care advances are needed to reduce ovarian cancer morbidity and mortality. 
Advances must, however, undergo a long, rigorously controlled research process that can take 
more than ten years before becoming available to the public.  Further, few women with 
persistent or recurrent ovarian cancer are offered or enrolled in the clinical trials that do exist at 
select sites throughout the nation. The purpose of this multiple-case study is to identify 
necessary and/or sufficient factors associated with enrollment in ovarian cancer clinical trials, 
and to identify facilitators and barriers within the practice setting that, in the longer term, can be 
used to inform targeted interventions to improve trial access and accrual.  The multilevel factors 
that were explored were aligned with the Consolidated Framework for Intervention Research 
(CFIR). The study sought to answer two research questions.  (1) Based on Qualitative 
Comparative Analysis [QCA (Ragin, 1989)], what necessary and/or sufficient factors would 
enable a woman with recurrent or persistent ovarian cancer to enroll in a clinical trial in Florida?  
(2) What barriers and facilitators, practitioner and patient-specific, exist with regard to enrolling 
women with ovarian cancer in clinical trials? 
Materials and Methods:  This multiple case study used online surveys to obtain quantitative and 
qualitative data from two populations:  women with ovarian cancer and nurses at various 
referring practice sites. Data from Moffitt Cancer Center’s Total Cancer Care protocol was 
requested to conduct chart reviews that would identify prospective participants. Qualitative 
comparative analysis (QCA), which is useful for determining causality in small sample sizes, 
was used to determine necessary and/or sufficient factors associated with enrollment by women 
ix	
	
with ovarian cancer in clinical trials, as well as barriers and facilitators related to clinical trial 
enrollment.  
Results:  Women with ovarian cancer who participated in clinical trials were stage III/IV, wanted 
information, and engaged in discussion about clinical trials, making those factors necessary for 
enrollment in a study.  Facilitators for participation were discussion with the provider of care, to 
some extent the existence of patient-accessible clinical trial literature in the practice, knowledge 
that health insurance covers standard of care costs, and having a provider who offers clinical 
trials. Absence of those factors thus constitutes a barrier.  For nurses, the impact of having a 
practice team plan was related to enrolling women with ovarian cancer in clinical trials, and 
feeling informed and comfortable with questions women might ask about trials. 
Conclusion:  Clinical trials are an underutilized priority for improving the standard of care and 
reducing the high rate of morbidity and mortality associated with ovarian cancer. The data show 
deficits and needs within two key interrelated populations: medical oncology practice nurses and 
women with ovarian cancer.  Opportunities exist within each level of the Consolidated 
Framework for Implementation Research (CFIR); interviews should be used to confirm the 
findings, which can be used to establish an interventional protocol to increase clinical trial 
enrollment by women with ovarian cancer.  
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CHAPTER ONE:  INTRODUCTION 
Statement of the Problem 
Ovarian cancer led to 14,180 deaths and 21,290 new diagnoses in 2015 (ACS, 2015).  
Ovarian cancer has had a relatively stable mortality rate since 1975 (NCI, 2013), despite a 
decrease in mortality for all gynecologic cancers combined.  Ovarian cancer, the most lethal 
gynecologic cancer, has a disproportionately high ratio of deaths to initial diagnoses when 
compared to other gynecologic cancers, as shown in Table 2.1 on page 7 (ACS, 2005a, 2009, 
2013b).  Ovarian cancer is usually diagnosed late in the course of the disease (stages III/IV) 
(Hansen et al., 1993) because (1) its subtle symptoms mimic other conditions (Smith et al., 
2005), (2) its low incidence compared to many other cancers makes it a rare cancer (ACS, 
2013b), (3) it should be but usually is not diagnosed, staged and initially treated by a 
gynecologic oncologist, who is specially trained and able to provide the quality standard of care 
(Goff, Matthews, et al., 2011; Goff, Miller, et al., 2011), (4) a screening test with sufficient 
sensitivity and specificity has yet to be achieved (Goff, 2012), and (5) few women with persistent 
or recurrent ovarian cancer are offered or enrolled in clinical trials (Morgan et al., 2013), despite 
the National Comprehensive Cancer Network (NCCN) guideline that women with persistent or 
recurrent ovarian cancer should be offered a clinical trial as a treatment option along with the 
standard-of-care (SOC) regimen. 
Need for the Study 
SOC advances, for preceding reasons, are needed to reduce ovarian cancer morbidity 
and mortality. Advances must, however, undergo a long, rigorously controlled research process 
that is regulated by the U.S. Food and Drug Administration (FDA) that can take more than ten 
years before becoming available to the public (FDA, 2012). The ovarian cancer SOC is 
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changing quickly, with evolving strategies being tested in clinical trials for their impact on overall 
and progression-free survival and quality of life. Strategies include the use of neoadjuvant 
therapy in advanced ovarian cancer, the use of biologic drugs that target specific gene 
pathways, the impact of various dose densities and delivery routes (intraperitoneal and/or 
intravenous), and the role of antiangiogenic drugs and maintenance therapies (Goff, 2013).   
Participation in cancer clinical trials by adults with even the most common cancers is 
well below 10 percent (Murthy, Krumholz, & Gross, 2004).  Most studies that have been done 
have focused on barriers and facilitators identified in groups of patients comprised of men and 
women of wide-ranging age with various cancers (Comis, 2000; Comis, Miller, Aldige, Krebs, & 
Stoval, 2003), or persons who responded to surveys that may never have had a diagnosis of 
cancer (Gullo, 2005b; Taylor & Leitman, 2002).  Some studies have focused on institutional 
barriers (Dilts & Sandler, 2006), but few have looked at trial enrollment barriers within a system 
linked to one type of subspecialty within a specific region, in the context of one type of cancer 
that is particularly deadly. 
Purpose of the Study 
The purpose of this multiple-case study is to identify necessary and/or sufficient factors 
associated with enrolling in clinical trials by women with persistent or recurrent ovarian cancer 
throughout the state of Florida, and to identify facilitators and barriers within the gynecologic 
oncology practice setting that, in the longer term, can be used to inform targeted interventions to 
improve trial access and accrual.  It is believed that the following research questions will help 
fulfill the purpose of the study. 
Research Questions 
1. Based on Qualitative Comparative Analysis [QCA (Ragin, 1989)], what 
necessary and/or sufficient factors enable a woman with recurrent or persistent 
ovarian cancer to enroll in a clinical trial in Florida? 
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2. What barriers and facilitators, practitioner and patient-specific, exist with regard 
to enrolling women with ovarian cancer in clinical trials? 
Overview of the Study 
The theoretical framework for this study is the Consolidated Framework for 
Implementation Research (CFIR), which is explained in chapter two.  The study populations are 
nurses in gynecologic or medical oncology practices, and women with ovarian cancer, identified 
via Moffitt’s Total Cancer Care clinical and biospecimen repository.  The TCC data was used to 
conduct chart reviews to identify 60 community- and hospital-based practices, comprised of 30 
gynecologic oncology and 30 medical oncology practices. Both study populations were 
surveyed, and questions included demographics and factors for dimensions of the CFIR 
theoretical model. Analysis of responses comprised descriptive statistics and Qualitative 
Comparative Analysis (QCA), explained in chapter three. 
Assumptions 
 Ovarian cancer is the deadliest of gynecologic cancers with a mortality rate that has 
been stable for more than three decades, the details of which are explained in chapter one.  
Despite rapid advances that are changing the standard of care to increase overall and 
progression-free survival and quality of life, ovarian cancer diagnoses are still made at 
advanced stages, when the disease usually will be terminal.  Curative and prevention-focused 
ovarian cancer clinical trials, therefore, remain a priority. The standard of care can improve only 
via the clinical trial process, and yet the rarity of ovarian cancer makes adequate accrual 
numbers for statistical power difficult to achieve. It is thus especially important that regional, 
statewide, and national accrual-promoting network strategies be developed and shared to 
increase opportunities for women with advanced disease to enroll in clinical trials. 
Significance 
This multiple case study attempted to identify necessary and/or sufficient factors related 
to enrolling women with ovarian cancer in clinical trials. The surveys blended demographics, 
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quantitative and qualitative data to blend information that would not only detect barriers and 
facilitators in practice settings, but also provide perceptions associated with conditions, 
intentions, and behaviors. Detection of specific barriers and facilitators, along with explanations, 
can guide further exploration for informed interventions to improve practice patterns and lay 
perceptions with regard to clinical trial enrollment for women with persistent or recurrent ovarian 
cancer. Subsequent intervention-focused research that strengthens ovarian cancer clinical trial 
networks can be used to establish a model with guidelines that can be followed statewide and 
beyond. 
Organization of Dissertation Proposal 
Chapter one is an introduction to the problem and the need for the study.  Chapter two is 
a literature review, describing the magnitude of the burden of ovarian cancer, as well as 
associated challenges in reducing the morbidity and mortality associated with a disease that has 
had a stable mortality rate for more than 30 years. Chapter two also discusses the theoretical 
model in which the study is grounded. Chapter three focuses on the research methods and 
analytic approach that was undertaken, explaining the research plan and research questions, as 
well as the study populations, study schema, recruitment plan and proposed timeline. Chapter 
four presents the results for the study populations, providing both descriptive statistics and QCA 
results for women with ovarian cancer and nurses in gynecologic oncology and medical 
oncology practices. Chapter five discusses the findings and their implications for public health 
and practice, as well as the challenges, strengths and weaknesses associated with the study, 
then concludes with recommendations.  
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CHAPTER TWO: LITERATURE REVIEW 
Background on Ovarian Cancer 
Morbidity and Mortality 
 Ovarian cancer will lead to 14,180 deaths and 21,290 new diagnoses in 2015 (ACS, 2015).  
Ovarian cancer has had a relatively stable mortality rate since 1975, as shown in Figure 2.1 
(NCI, 2013), despite a decrease in mortality for all gynecologic cancers combined.  Ovarian 
cancer, the most lethal gynecologic cancer, has a disproportionately high ratio of deaths to initial 
diagnoses when compared to other gynecologic cancers (see Table 2.1).   
Nearly 90% of ovarian tumors arise from the epithelial cells on the surface of the ovary 
(Fathalla, 1971; Rosen et al., 2009), and most are of the serous pathologic histotype, which is 
classified as low grade or high grade on the basis of the extent of nuclear atypia and mitosis 
(Malpica et al., 2004). Low- and high-grade ovarian cancers differ at the genomic and molecular 
levels; low grade has less molecular abnormalities than high-grade carcinoma, which is more 
aggressive and less responsive to standard-of-care treatment (Rosen et al., 2009). 
Causes and Risks  
Most epithelial ovarian cancers are diagnosed at advanced stages (III-IV), when the 
disease is not likely to be curable (Hansen et al., 1993).  Although the cause of ovarian cancer 
is not known, several hereditary risk factors may be responsible for ovarian cancers in up to 
10% of women:  (1) having two or more first-degree relatives with ovarian cancer, (2) having a 
positive BRCA1/2 genotype status, and (3) having a family history of hereditary nonpolyposis 
colorectal cancer (HNPCC) (Finch et al., 2006; Fleming, Ronnett, & Seidman, 2009).    
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Figure 2.1. Age-Adjusted U.S. Mortality Rates by Cancer Site. All Ages, All Races, Female,  
1975-2009 
 
Table 2.1. Gynecologic cancer incidence, mortality, and ration of mortality to incidence  
(ACS, 2005b, 2009, 2013b) 
 
Site 
2005 2009 2013 
Incidence Mortality 
Ratio of 
deaths to 
new 
cases 
Incidence Mortality 
Ratio of 
deaths 
to new 
cases 
Incidence Mortality 
Ratio of 
deaths 
to new 
cases Ovary 22,220 16,210 0.73 21,550 14,600 0.68 22,240 14,030 0.63 
Vagina 2,140 810 0.38 2,160 770 0.35 2,890 840 0.29 
Cervix 10,370 3,710 0.36 11,270 4,070 0.36 12,340 4,030 0.33 
Vulva 3,870 870 0.22 3,580 900 0.25 4,700 990 0.21 
Uterus 40,880 7,310 0.18 42,160 7,780 0.18 49,560 8,190 0.16 
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Risk is increased by nulliparity or being older than 35 years at first birth and possibly 
having hormone therapy (Morch, Lokkegaard, Andreasen, Kruger-Kjaer, & Lidegaard, 2009).   
Factors that may reduce risk include being 25 or younger at first birth and having used oral 
contraceptives (Fleming et al., 2009).  Age at first birth and use of oral contraceptives are 
believed to affect risk because of their influence on the number of total lifetime ovulations and 
exposure to estrogen (Kaga et al., 1996; Riman, Persson, & Nilsson, 1998; Rossouw et al., 
2002). Also believed to affect risk is breastfeeding, for its effect on reducing ovulations and thus 
lessening continuous trauma to the epithelium (Fleming et al., 2009).  That trauma, followed by 
epithelial cell proliferation, has been suspected to promote mutations or carcinogenesis, a 
hypothesis supported by studies that have correlated suppression of ovulation by oral 
contraceptives and/or pregnancy with reduced risk of ovarian cancer (Casagrande et al., 1979; 
Tung et al., 2005).  Advances in cytogenetics, the study of human chromosomes and their 
relation to disease, and histopathology, the tissue changes associated with disease, have led to 
the knowledge that type I, low grade, generally means the patient will have a good prognosis, 
and type II, high grade, tends to be aggressive and suggests a poor prognosis (Kurman, 
Visvanathan, Roden, Wu, & Shih Ie, 2008).  Gene expression profiling has reached from 
research laboratories into the clinical practice setting, allowing thousands of genes to be 
measured at one time to generate expression profiles that can be used to predict prognosis and 
therapeutic strategies (Chon & Lancaster, 2011; Dressman et al., 2007; Lancaster et al., 2006). 
Prevention and Screening 
Because the precise cause of ovarian cancer is not known, even though some risk 
factors have been identified, clear-cut guidelines for preventing ovarian cancer do not exist 
(Petroff, 2012).  The risk factors in the preceding section, however, suggest that certain 
behaviors may moderate risk for acquiring ovarian cancer.  Women with two or more first-
degree relatives who have been diagnosed with ovarian cancer can be tested for the BRCA1/2 
or HNPCC gene mutation, and if the results are positive they may opt for more intensive 
8	
	
surveillance or prophylactic oophorectomy, removal of the ovaries (Whittemore, Harris, & Itnyre, 
1992b).  Hereditary gene mutations, however, account for only up to 10% of ovarian cancers 
(Ramirez, Chon, & Apte, 2011; Whittemore, Harris, Itnyre, & Halpern, 1992). 
A screening test with adequate sensitivity and specificity has yet to be developed, and 
efforts to create a cost-effective screening test are hampered by lack of an in situ lesion, (Harris, 
Whittemore, & Intyre, 1992), and diagnosis requires a major operative procedure (laparotomy or 
laparoscopy) (Whittemore, Harris, & Itnyre, 1992a).  Furthermore, screening should ensure that 
early-detection benefits outweigh morbidity/mortality risk (Whittemore, Harris, Itnyre, et al., 
1992), which is impeded by the low incidence rate of ovarian cancer; for example, in women 
over 50 there are 40 cases per 100,000 women (Horn-Ross, Whittemore, Harris, & Itnyre, 
1992).  Goff (2012) explained how low incidence impedes the development of a perfect 
screening test, which would require 2,500 screens 
… to detect 1 case of ovarian cancer.… if a screening test has only a 1% false-
positive rate (sensitivity of 99%), then of every 2,500 women screened 25 would 
have false-positive tests yielding a positive predictive value (PPV) of 4%. … a 
screening test that results in a major surgical procedure should have a PPV of at  
least 10%. That means for every case of cancer detected there would be no 
more than 10 “unnecessary” surgeries (false positives). With an incidence of 40 
in 100,000, a screening test would need a specificity of 99.6% or a false-positive 
rate of less than 0.4% to have a PPV of 10% or higher. … Because 2,500 
women need to be screened to detect a single ovarian cancer, the cost must be 
affordable, and the test readily available and acceptable to patients (p. 184). 
In addition to low incidence, barriers to screening and prevention include difficulty in 
visualizing early stage changes and the use of laparoscopic tissue sampling only for diagnostic 
purposes, thus limiting the availability of tissue-based biomarkers for prevention trials (Petroff, 
2012).  In the absence of concrete data on ovarian cancer etiology, because breast and ovarian 
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cancers share common risk factors, Petroff (2012) suggested that prevention should be pursued 
by developing dual breast-ovarian cancer prevention guidelines.  Commonalities between 
breast and ovarian cancers include estrogen exposure, BRCA1/2 mutations, and suspected 
lifestyle factors that include obesity, age at first childbirth, and age at menarche and menopause 
(Brekelmans, 2003). 
The Society of Gynecologic Oncologists (SGO) does not recommend use of two recently 
developed biomarker assessment screening tools:  (1) OVA1 (Vermillion, Inc., Austin, Texas), 
that measures transthyretin, apolipoprotein A1, transferrin, beta-2 microglobulin, and CA-125 to 
assess referrals for surgery, and (2) OvaSure (LabCorp, Burlington, North Carolina), that 
assesses leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, 
and cancer antigen (CA) 125 (Whittemore, Harris, et al., 1992b). 
The U.S. Preventive Services Task Force, based on evidence that annual transvaginal 
ultrasonography and testing for the serum tumor marker CA-125 failed to reduce the number of 
ovarian cancer deaths, recommends against ovarian cancer screening for women of average 
risk (Harris et al., 1992).  For women with a family history of ovarian cancer, genetic testing is 
recommended, followed by counseling about whether to pursue frequent surveillance with or 
without prophylactic oophorectomy (Force, 2005; Menon & Jacobs, 2001; Poovorawan et al., 
2011; Whittemore, Harris, Itnyre, et al., 1992) 
Detection of Ovarian Cancer 
According to the American College of Obstetrics and Gynecology (ACOG), the best way 
to detect ovarian cancer is for both the patient and her physician to suspect the diagnosis 
because she is symptomatic (Whittemore, Harris, et al., 1992a).  SGO has stated that despite 
the fact that most women with ovarian cancer have symptoms, they remain undiagnosed for 
many months (Whittemore, Harris, Itnyre, et al., 1992).    
 Symptoms experienced prior to diagnosis, as revealed by a survey of 1,725 U.S. and 
Canadian women with ovarian cancer included, in order of prevalence from greatest to least: 
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increased abdominal size, bloating, fatigue, abdominal pain, indigestion, urinary frequency, 
pelvic pain, constipation, back pain, pain with intercourse, inability to eat normally, palpable 
mass, vaginal bleeding, weight loss, nausea, bleeding with intercourse, diarrhea, and deep vein 
thrombosis; 5% of women experienced no symptoms (Horn-Ross et al., 1992).  In Goff’s study 
(2012), 89% of women with early stage disease had symptoms prior to being diagnosed, and 
their symptoms did not differ from those experienced by women with advanced-stage disease.  
No available test has been shown to detect ovarian cancer reliably, at an early, curable stage (I-
II), thus to optimize the chance for a timely diagnosis, educating women and practitioners about 
symptoms and prompt initiation of a diagnostic regimen is essential (Whittemore, Harris, et al., 
1992a; Whittemore, Harris, Itnyre, et al., 1992).   
 An ovarian cancer diagnosis is generally precipitated by a suspicious palpable pelvic 
mass, ascites, and/or abdominal distention, accompanied by symptoms that may include 
bloating, pain, difficulty eating, feeling full quickly, and having urinary symptoms of urgency or 
frequency (Goff, Mandel, Muntz, & Melancon, 2000). The diagnostic protocol includes family 
history, an abdominal/pelvic exam, gastrointestinal evaluation if clinically appropriate, ultrasound 
and/or pelvic computed tomography (CT) scan, chest imaging, measure of CA-125, and  
complete blood count and chemistry profile (Morgan et al., 2011; Morgan et al., 2013). 
Staging and Treatment 
Staging. The treatment plan is dictated by ovarian cancer staging, using a valid and 
reliable evidence-based approach to cancer as classified by the International Federation of 
Gynecology and Obstetrics (FIGO) staging system  (Ness et al., 2002).  Table 2.2 explains 
ovarian cancer stages, for which FIGO established guidelines as early as 1973 (Ness et al., 
2002).   
Surgery.  The staging process requires removal of the ovaries, fallopian tubes, and 
uterus, as well as extra-ovarian sites such as lymph nodes, peritoneum, and omentum, which 
can harbor cancer cells (Schorge, Eisenhauer, & Chi, 2012).  In 1994 the National Institutes of 
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Health (NIH) published guidelines on ovarian cancer treatment that made the complete staging 
procedure the standard of care (NIH, 1994).  A woman with a pelvic mass will receive 
cytoreductive surgery, or debulking, for stages II, III, and IV for the purpose of removing as 
much cancer as possible to promote drug delivery to smaller tumors with good blood supply, 
remove drug resistant clones to reduce the likelihood of early drug resistance, and remove 
tumors in locations that could lead to bowel obstruction (Schorge et al., 2012). Surgical 
debulking is usually done by laparotomy or total abdominal hysterectomy, bilateral salpingo-
oophorectomy with comprehensive staging (or unilateral salpingo-oophorectomy for stages 1A 
to 1C) (Morgan et al., 2011; Morgan et al., 2013).  Gynecologic surgeons attempt to remove all 
 
Table 2.2. FIGO Staging for Ovarian Cancer, adapted from (Purdie, Bain, Siskind, Webb, & 
Green, 2003) 
 
Stage I Limited to ovaries 
Ia Limited to 1 ovary, no ascities with malignant cells; no tumor on surface; intact capsule 
Ib Limited to both ovaries; no ascites with malignant cells;  no tumor on surface; intact capsules 
Ic Either 1a or 1b, but tumor on surface of one or both ovaries, or capsule ruptured, or ascites with malignant cells or positive peritoneal washings 
Stage II Involving 1 or both ovaries with pelvic extension 
IIa Extension and/or metastases to the uterus and/or tubes 
IIb Extension to other pelvic tissues 
IIc 
Either IIa or IIb, but tumor on surface of either or both ovaries, or with capsule)s_ 
ruptured, or with ascites containing malignant cells, or with positive peritoneal 
washings. 
Stage III 
Involving 1 or both ovaries with peritoneal implants outside the pelvis and/or 
positive retroperitineal or inguinal nodes. Superficial liver metastases.  Tumor is 
limited to pelvis, but with malignant extension to small bowel or omentum. 
IIIa 
Grossly limited to true pelvis, with negative nodes, but histologically confirmed 
microscopic seeding of abdominal peritoneal surfaces, or histologic proven 
extension to small bowel or mesentery. 
IIIb 
Involves 1 or both ovaries with confirmed implants, peritoneal metastasis of 
abdominal peritoneal surfaces, none greater than 2 cm in diameter; negative 
nodes. 
IIIc Peritoneal metastasis beyond pelvis greater than 2 cm in diameter and/or positive retroperitoneal or inguinal nodes. 
Stage IV 
Involves 1 or both ovaries with distant metastases.  If pleural effusion is present, 
there must be positive cytology to allot a case to Stage IV.  Parenchymal liver 
metastasis equals Stage IV. 
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of the tumor, and if that is not possible, they try to leave no more than one centimeter in 
diameter of tumor tissue, which is called optimal cytoreduction, versus suboptimal, indicating 
more than a centimeter of residual disease (Ness & Cottreau, 1999).  In the 10% of cases that 
are diagnosed in women under 40, fertility-sparing surgery can be considered when cancer is 
limited to one ovary, especially if it is low grade (Schorge et al., 2012).  Multiple surgeries are 
likely in women with advanced (stage III/IV) disease as tumors become chemoresistant and 
recur. 
Chemotherapy.  Staging (see Figure 2.2, below), determination of histopathologic tumor 
type, and disease history (recurrence and response to prior therapies) will guide the selection of 
chemotherapeutic agents; neoadjuvant chemotherapy, using pre-operative tumor-reducing 
chemotherapy, may be advised for bulky stage III/IV disease. 
 
Figure 2.2. Adjuvant/Primary (first-line) Chemotherapy by Stage (Adapted from Morgan, 2013) 
 
Stage IA/IB.  The current standard of care for stage IA/IB patients, if grade 1, following 
surgery, is observation; if a woman’s ovarian cancer is grade 2, she may be observed or given 3 
Stage IA or IB 
Grade 1 
Grade 2 
Grade 3 
or clear  
cell 
Observe 
Observe or 
IV taxane/carboplatin 3-6 cycles 
IV taxane/carboplatin 3-6 cycles 
Stage IC 
Stage II, III, IV 
• IP chemotherapy in optimally 
debulked Stage II/III or 
• IV taxane/carboplatin 6-8 
cycles 
• Completion surgery per 
response & resectability 
• Neoadjuvant bulky III/IV 
IV taxane/carboplatin 3-6 cycles 
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to 6 cycles of an intravenous taxane with carboplatin; if grade 3, she will be advised to receive 
the preceding chemotherapy (Morgan et al., 2013) 
Stage IC.  Stage IC, any grade, calls for 3 to 6 cycles of intravenous taxane/carboplatin.  
Stages II - IV.  Women who are stage II through IV may have intraperitoneal or 
intravenous delivery of platinum-based therapy, perhaps with subsequent surgery, following 
neoadjuvant chemotherapy, or secondary, tertiary, or palliative (Schorge et al., 2012).  
Intraperitoneal delivery of chemotherapy, versus intravenous delivery, provides direct exposure 
that has been shown to prolong overall and progression-free survival in advanced ovarian 
cancer for up to 16 months (Kalaaji et al., 2012; Lalwani et al., 2011; Wenzel, Anderson, et al., 
2007).   
Most women who are diagnosed at Stage III/IV and who respond to platinum-based 
therapy will have recurrent disease, and some will become resistant to platinum therapy earlier 
than others. As platinum resistance increases, additional cytotoxic drugs will be introduced, 
among them docetaxel, gemcitabine, doxorubicin, etoposide, topotecan, cyclophosfamide, 
capecitabine, ifosfamide, and oxaliplatin. In addition to cytotoxic drugs, hormonal therapies such 
as anastrozole, letrozole, and tamoxifen may be effective, as well as targeted therapy with 
bevacizumab, that inhibits vascular endothelial growth factor (VEGF) (Morgan et al., 2011; 
Morgan et al., 2013).  Notably, the National Comprehensive Cancer Network (NCCN) Clinical 
Practice Guidelines in Oncology (page 89) state that women with persistent or recurrent ovarian 
cancer, which comprises most women with the disease, should be offered a clinical trial 
(Morgan et al., 2011; Morgan et al., 2013). 
Disparities 
Ovarian cancer incidence is highest in white women (8.4 per 100,000), followed by black 
women (6.7 per 100,000), Hispanic women (5.8 per 100,000), American Indian/Alaska Native 
women (5.5 per 100,000), and Asian/Pacific Islander women (4.8 per 100,000 women) (NCI, 
2013).   Although a slight improvement in mortality occurred over the last 30 years, survival in 
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black women is worse than that of white women (Nayak et al., 2011).  The five-year survival rate 
for white women improved from 37% to 45% between 1975 and 2004, but for black women it 
decreased from 43% to 38% during the same time span (Jemal et al., 2009).  In spite of 
published guidelines, only 50% of U.S. women with ovarian cancer undergo the correct 
procedure; most who were inaccurately staged in a study were poor, elderly, black or Hispanic 
(Goff et al., 2007). 
      In a meta-analysis, Terplan and colleagues searched MEDLINE, PsychInfo, and 
EMBASE for ovarian cancer studies that reported race for women who were treated in North 
America (Terplan, Smith, & Temkin, 2009).  The greatest advance in ovarian cancer survival 
emerged with platinum-based chemotherapy in the 1980s, it is thus important to note that black-
white survival disparities emerged after 1985. The researchers therefore suggest that black-
white ovarian-cancer survival disparity may result from inequitable access to care (Terplan et 
al., 2009). 
A cross-sectional study of 13,858 women (891 black and 12,967 white) diagnosed with 
epithelial ovarian cancer between 1981 and 2000, whose records were in the Florida Cancer 
Data System (FCDS), revealed racial differences in patterns of care among women living in 
Florida (Williams, Stockwell, Hoffman, & Barnholtz-Sloan, 2010).  Black women diagnosed with 
advanced disease were not as likely to receive chemotherapy, even though they were younger 
on average than white women in the study, which, in light of the disparity that is discussed 
below with regard to older women, raises a red flag on the impact of race on access to the 
standard of care.  
Women in lower income neighborhoods who were under/uninsured had worse outcomes 
than women of better means because of limited options that force them to seek care at public 
hospitals, where they are likely to receive substandard care without correct staging and 
chemotherapy (Boyd, Novetsky, & Curtin, 2011; Chan et al., 2008).  Women who live in rural 
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and western regions have worse outcomes than women in metropolitan and eastern regions 
who receive care from board-certified subspecialists (Riman et al., 1998).   
In spite of published guidelines, only half of U.S. women with ovarian cancer undergo 
the correct procedure; most who were inaccurately staged in a study were poor, elderly, black or 
Hispanic (Goff et al., 2007). The disparity in Hispanic women may be greater than known; some 
studies have excluded them because their numbers were too small in the populations of study 
(Williams et al., 2010).  Moreover, despite the guideline that women with persistent or recurrent  
ovarian cancer should be offered a clinical trial as a treatment option, many women over 65, 
regardless of their race/ethnicity, are not offered clinical trials because of preconceived notions 
that older patients will be less compliant and prone to complications related to comorbidities 
(Harter et al., 2005) 
Impact of Ovarian Cancer on Quality of Life 
Advanced ovarian cancer and its treatment are life-altering states of being with serious 
physical, mental, and social consequences.  Physical difficulties include recovery from major 
abdominal surgery and side effects from platinum-taxane chemotherapy that include fatigue, 
nausea, neurotoxicity, alopecia, neutropenia, myelosuppression, and stomatitis (Grzankowski & 
Carney, 2011). Major surgery can lead to postoperative complications such as bleeding, 
pulmonary emboli, wound or urinary tract infections, dehydration, and fluid/electrolyte 
imbalances; upon healing, women face chemotherapies, either intravenously (IV) or 
intraperitoneally (IP), whose side effects can include nausea, fatigue, and neuropathy 
(Bohnenkamp, LeBaron, & Yoder, 2007a, 2007b).  While IP therapy has been shown to improve 
overall survival by nearly 16 months, a GOG study that compared IV and IP side effects found 
the latter to be significantly greater and to include neurotoxicity and abdominal discomfort 
(Wenzel, Huang, et al., 2007). Women being given palliative chemotherapy for terminal disease 
expect that it will make them feel better, delay further problems, make them live longer, and 
even cure their disease (Doyle, Crump, Pintilie, & Oza, 2001); unrealistic expectations may lead 
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them to tolerate side effects that they would not normally accept if they had a more realistic 
perspective of the limitations of palliative chemotherapy, perhaps helping them to transition into 
hospice earlier, where quality of life is the priority.  
           Having advanced ovarian cancer with a poor prognosis can lead or often leads to anxiety 
and depression (Grzankowski & Carney, 2011), and many women have significant stress as 
they await tumor marker test results that are an ongoing part of surveillance (Parker et al., 
2006). Women whose subtle symptoms were presumed to be common gastrointestinal ailments 
and were later diagnosed with advanced disease can harbor provider mistrust (Walker & 
Robinson, 2009).  Initial surgery is often driven by urgency related to increasing discomfort, and 
women are often triaged to general surgeons. Upon learning the diagnosis postoperatively, a 
patient’s mistrust may further be compounded by discovering a gynecologic oncologist is 
specially trained for accurate staging, optimal cytoreduction, and intraperitoneal port placement, 
all of which comprise life-extending ovarian-cancer standard-of-care procedures (Engelen et al., 
2006). 
Social issues include strained interpersonal relations resulting from time constraints 
imposed by medical visits, treatment and recovery.  A couple’s intimacy can be compromised by 
sexual dysfunction from fatigue, vaginal dryness from surgery-related nerve damage, anxiety, 
depression, or negative body-image perceptions (Grzankowski & Carney, 2011).  Women may 
lose jobs because of illness-related absences, thus losing health insurance when they most 
need it (Tunceli, Short, Moran, & Tunceli, 2009).   
Gynecologic Oncologists, Targeted Therapies, and Clinical Trials 
Inequitable Access to Gynecologic Oncologists 
It is known that treatment for ovarian cancer by a gynecologic oncologist yields accurate 
staging, optimal treatment according to national guidelines, the opportunity for a clinical trial, 
and access to better outcomes and quality of life.   Women treated by a gynecologic oncologist 
had four times the probability of receiving recommended staging procedures compared to those 
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not treated by a gynecologic oncologist (Cress et al., 2011).  In a study of the U.S. distribution of 
gynecologic oncologists that was sponsored by the Division of Cancer Prevention and Control 
(DCPC) within the Centers for Disease Control (CDC) starting in 2008, the investigative team 
reported at the 2011 annual meeting of the Society of Gynecologic Oncologists that more than 
99% of gynecologic oncologists practice in metropolitan counties, thus few were found in 
nonmetropolitan counties, and none were found in rural counties (Cooney et al., 2011).  The 
CDC ovarian-cancer workgroup has emphasized the need to find ways to better communicate 
with and educate primary care doctors in referring women for follow-up diagnostic tests 
(Newkirk, Biesinger, Chon, Yokomori, & Xie, 2011).  
Awareness of Genomic Research for Improved Care Through Targeted Therapies 
Genomics has opened the door to an exciting array of therapies that target specific 
molecular pathways and have the potential to interfere with tumor growth and survival 
(Lancaster et al., 2006).  Genomic oncology holds promise for a major transformation in 
oncology standards of care; emerging biologic therapies have the potential to moderate the use 
of cytotoxic drugs, thus improving outcomes while diminishing side effects and toxicities 
associated with traditional chemotherapies (Chon & Lancaster, 2011).   
Awareness of and Access to Clinical Trials 
The CDC has asserted the importance of collaborative efforts among federal agencies 
and public health partners to identify resources to  remove barriers to participation in clinical 
trials by women with ovarian cancer (Trivers, Stewart, Peipins, Rim, & White, 2009).   NCCN 
guidelines assert that a clinical trial should be an option for women with persistent or recurrent 
ovarian cancer (Morgan et al., 2011; Morgan et al., 2013).  In spite of the direct relationship 
between clinical trials and improved standards of care, a cross-sectional population-based 
analysis of the NCI Clinical Trial Cooperative Group breast, colorectal, lung and prostate cancer 
studies from 2000 to 2002 revealed that cancer trial enrollment was low for all patient groups, 
with ethnic minorities, women, and the elderly less likely to enroll in cooperative group trials than 
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whites, men, and younger patients (Murthy et al., 2004).  Although participation in clinical trials 
by all adults with cancer has been low historically, improved survival rates in women with 
ovarian cancer have been linked to clinical trials (Chan et al., 2006).  
Clinical Trial Process, Phases, Sponsors, and Protections 
The lengthy process of developing new therapies, which can span 15 years from 
preclinical bench to clinical trials to approval for use in patients, is rigorously managed and 
overseen by the U.S. Food and Drug Administration (FDA). The steps in the approval process 
are summarized in Table 2.3 (FDA, 2012).  
Phase I, II, and III clinical trials test a drug or device sequentially (see Table 2.4). 
Researchers may combine a study as a Phase I/II or II/III trial in one protocol, which aids a more 
expedient transition between phases. Less commonly used are Phase 0 and IV studies.  Phase 
0 refers to extremely small studies to help a researcher determine whether a new agent should 
be tested in a Phase I trial.  
 
Table 2.3. Drug Review Steps Simplified (FDA, 2012) 
 
1. Preclinical (animal) testing. 
2. An investigational new drug application (IND) outlines what the sponsor of a new drug 
proposes for human testing in clinical trials. 
3. Phase 1 studies (typically involve 20 to 80 people). 
4. Phase 2 studies (typically involve a few dozen to about 300 people). 
5 Phase 3 studies (typically involve several hundred to about 3,000 people). 
6. The pre-NDA period, just before a new drug application (NDA) is submitted. A common 
time for the FDA and drug sponsors to meet. 
7. Submission of an NDA is the formal step asking the FDA to consider a drug for marketing 
approval. 
8. After an NDA is received, the FDA has 60 days to decide whether to file it so it can be 
reviewed. 
9. If the FDA files the NDA, an FDA review team is assigned to evaluate the sponsor's 
research on the drug's safety and effectiveness. 
10. The FDA inspects the facilities where the drug will be manufactured as part of the approval 
process. 
11. FDA reviewers will approve the application or issue a complete response letter. 
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Phase IV trials monitor long-term safety and effectiveness and run after a new treatment 
has been approved and is on the market (NCI, 2014). 
Sponsors of Cancer Clinical Trials 
Trial sponsors can be from private industry such as a pharmaceutical company, federal 
agencies such as the National Cancer Institute or the Department of Defense,  or private 
nonprofit foundations who are advocates for education and research related to a specific 
disease, for example the Ovarian Cancer Research Foundation (OCRF) (OCNA, 2014). 
Human Subjects Protections and Regulatory Policies 
Cancer clinical trial protocols are first approved by scientific experts that comprise 
Scientific Review Committees (SRC) within a facility that offers a study, before being reviewed 
by an institutional review board (IRB).  When a study has been approved by the preceding 
authorities, after it is launched it is monitored by the SRC and IRB, as well as an external Data 
and Safety Monitoring Board (if a Phase III study), and by the research team and the actual trial 
sponsor (NCI, 2012). 
 
Table 2.4. Clinical Trials, Phases I, II, III Briefly Described. Adapted from (NCI, 2014) 
 
Phase I • To find a safe dose 
• To decide how a new treatment should be given (orally, 
intravenously, for example) 
• To see how the new treatment affects the human body 
15 – 30 
participants 
Phase II • To determine if the new treatment affects a certain cancer 
• To see how the treatment affects the human body. 
Less than 
100 
participants 
Phase III • To compare the new treatment (or new use of an existing 
treatment used in another way) with the current standard 
treatment 
100 to 
several 
thousand 
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Key Persons Within the Practice Setting Involved in the Ovarian Cancer Clinical Trial 
Enrollment Process. 
The person with the greatest influence on a woman with ovarian cancer, in accordance 
with what the literature on high patient regard for physician opinion, is the gynecologic 
oncologist, who can raise awareness of and direct women in finding appropriate clinical trials. 
Moreover, a portion of gynecologic oncologists may actually be principal investigators of clinical 
trials. Also in a position to be influential in raising awareness and supporting women in finding 
clinical trial resources are midlevel practitioners who see existing patients and monitor them 
during surveillance, which puts them in a prime position to notice if serum CA125 levels appear 
to be rising or other symptoms are emerging that may signal a possible recurrence. Outpatient 
and inpatient nurses also spend time with their patients, perhaps more time than any other 
provider, and are in a prime position to share information about clinical trials. A very important 
provider in the institution and larger practice setting is the research nurse or study coordinator, 
whose entire job is dedicated to clinical trial enrollment and monitoring of participants 
throughout a study and for many months after treatment is completed. Often, however, a patient 
does not speak with a research nurse until interest has been expressed either by the physician 
or the patient in a clinical trial. It may thus be important to educate primary nurses so that they 
can provide basic clinical research education that may lead to conversations about clinical trials 
between patients and research nurses that might otherwise have been missed opportunities.    
The Need for Enrollment in Ovarian Cancer Clinical Trials 
Progress in preventing and curing cancer depends on informed participation in cancer 
clinical trials (Comis, 2000).  As the biomedical understanding of cancer expands, increasing 
opportunities to test preventive, curative and palliative advances will require increasing numbers 
of adults who are able to make informed decisions about participation in clinical trials (Comis et 
al., 2003).  Enrollment in cancer clinical trials has been consistently low in U.S. adults (Murthy et 
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al., 2004), and accrual barriers have been studied, with results calling for interventions to 
facilitate increased enrollment.   
Informed decision-making about cancer clinical trials should occur as early as possible in 
the treatment continuum; enrollment criteria usually limit eligibility by capping the allowable 
number of prior therapies to up to three, except in phase I studies that are more focused on how 
much of an agent can be administered safely rather than on therapeutic benefit (Daugherty et 
al., 1995).  Eligibility criteria require adequate performance status, thus waiting until multiple 
therapies have failed and advanced disease has led to poor health may make eligibility for a 
clinical trial unlikely, particularly for older patients, who may have more comorbidities and, while 
at the greatest risk for cancer, are already underrepresented in clinical trials (Lewis, 2003).     
Ovarian cancer, the most lethal gynecologic cancer with a mortality rate that has been 
stable for more than three decades (ACS, 2013b), should be diagnosed and treated by a 
gynecologic oncologist per National Comprehensive Cancer Network (NCCN) guidelines 
(Stewart, Rim, & Richards, 2011).  NCCN guidelines stipulate that women with persistent or 
recurrent ovarian cancer should be offered a clinical trial (Morgan et al., 2011; Morgan et al., 
2013), because trials are a prerequisite to progress, which has extended survival in women with 
advanced disease (Engelen et al., 2006), but failed to yield a curative discovery or preventive 
screening test (ACS, 2013a).   
The ovarian cancer SOC is changing quickly, with evolving strategies being tested in 
clinical trials for their impact on overall and progression-free survival and quality of life. 
Strategies include the use of neoadjuvant therapy in advanced ovarian cancer, the use of 
biologic drugs that target specific gene pathways, the impact of various dose densities and 
delivery routes (intraperitoneal and/or intravenous), and the role of antiangiogenic drugs and 
maintenance therapies (Goff, 2013). 
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Barriers 
The geographic influence of access to NCI-designated comprehensive cancer centers and 
gynecologic-oncologist principle investigators who oversee clinical trials is a significant barrier 
for women in rural and western regions of the United States (Riman et al., 1998), as discussed 
in the paper that addressed question 2.  However, even in major metropolitan areas where 
leading subspecialty clinical research resources are accessible, women lack awareness and 
have misperceptions about clinical trials that impede participation in much-needed ovarian 
cancer clinical trials (Comis et al., 2003). Nonparticipation is compounded by the low incidence 
and prevalence of ovarian cancer, challenging research-focused cancer centers to find 
adequate numbers of participants for randomized clinical trials with sufficient statistical power. 
The challenge of achieving adequate sample size has been aided by the collaborative efforts of 
the Gynecologic Oncology Group (GOG).  Comprised of more than 50 academic centers and 
160 affiliate sites, the GOG was established in 1970 to sponsor controlled clinical trials to 
answer questions about managing gynecologic cancers; to date, the GOG has conducted more 
than 300 studies and published more than 550 manuscripts (GOG, 2013).  
Numerous combined-gender studies of adults have identified barriers to participation 
that include lack of awareness that clinical trials are an option and the presumption that the 
standard of care is better than the investigational agent (Taylor & Leitman, 2001).  Deterrents of 
participation in clinical trials that have been found in multiple studies include concerns about 
randomization and placebos, being treated like a “guinea pig,” encountering unpleasant side 
effects, receiving a treatment that is inferior to the standard of care, and worry about cost, time, 
travel, and the complexity of the informed consent process.   Interestingly, Taylor and Leitman 
(2001) found that among the 85% of cancer patients who said they were unaware that clinical 
trials were an option, 75% said they would have attempted to enroll if they had known. 
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Facilitators 
 Physician-based facilitators in women with gynecologic cancers were studied by Luck 
and colleagues (2005), who found that women with a gynecologic oncologist for initial surgery 
were more likely to enroll in clinical trials (P<0.001).  Physicians who were primary investigators 
were more likely to enroll patients in clinical trials (Mannel et al., 2003), while physicians with an 
affiliative (friendly) communication style, as opposed to a dominant (controlling and contentious) 
style, positively influenced patients who enrolled in clinical trials (Grant, Cissna, & Rosenfeld, 
2000).   
Surveyed clinical-trial participants (men and women with various types of cancer) said 
they were motivated to advance medical science and help others, earn extra money, get better 
treatment, improve health, respond to information seen or heard about the study, follow a 
doctor’s recommendation, satisfy curiosity about a study, and, least often, seek a trial because 
of the severity of their illness (Gullo, 2005a; Taylor & Leitman, 2003).  An observational cohort 
of patients, physicians, and nurses revealed the following patient-based correlates of 
significance for clinical trial entry:  perceived benefits and having the help of a clinical research 
associate (CRA), doctor, or trial nurse in making the decision (P<0.05) (Wright et al., 2004).   
In a breast-cancer patient population, physician recommendation was a significant factor 
in a woman’s decision to enroll (Avis, Smith, Link, Hortobagyi, & Rivera, 2006).  Studies of 
facilitators in women with gynecologic cancers were associated with being 50 years of age or 
younger, having education beyond high school, and having private insurance (Mathews, 
Restivo, Raker, Weitzen, & Disilvestro, 2009).  Facilitators in women with gynecologic cancers 
that are similar to those found in mixed-gender populations include helping others, the need for 
follow-up care, and protecting personal health (Shuhatovich et al., 2005).   
Additional Challenges Associated with Ovarian Cancer Clinical Trials 
Because the incidence of ovarian cancer is lower than that of many other cancers, it is 
more challenging to get significant enrollment in ovarian cancer clinical trials. The GOG has 
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assisted in meeting that challenge by forming collaborative networks comprised of cancer 
treatment centers throughout the United States to support large multisite clinical trials (GOG, 
ND). The concentration of gynecologic oncologists in US metropolitan areas, noted by Cooney 
and colleagues (2011), translates into a shortage of those best able to lead ovarian cancer 
clinical trials as principle investigators. Thus there are regional limitations that decrease access 
to ovarian cancer clinical trials by women with advanced recurrent or persistent disease.  
Ovarian Cancer Clinical Trial Resources in Florida 
Florida, among the top half of states with a higher incidence of ovarian cancer (Figure 
2.3), has about 85 gynecologic oncologists, dispersed mostly in counties with large cities, such 
as Tampa, Orlando, Jacksonville, and Miami (Figure 2.4).  
 
	
Figure 2.3. Invasive Cancer Incidence Rates by State in the United States	
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Figure 2.4. Distribution of Gynecologic Oncologists in Approximated Upper, Middle, and Lower 
Thirds of Florida	
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Ovarian Cancer Clinical Trial Resources in Florida 
Gynecologic Oncologists 
 Based on the preceding literature, physician recommendation has the greatest impact on 
a patient’s decision-making about clinical trials. One of the greatest clinical trial resources for 
women with ovarian cancer is, therefore, gynecologic oncologists who inform them about 
opportunities for clinical trials either on-site or at another facility. 
 An informal web search of ovarian cancer clinical trials in Florida for women with 
recurrent disease, via FloridaCancerTrials.org, done on December 30th, 2013, revealed 38 
studies (three phase III studies in Tampa and Orlando; four phase II studies in Tampa, Orlando, 
and Jacksonville; eight phase I/II studies mostly in Tampa and Orlando, also Sarasota; and 
fourteen phase I studies, predominantly in Tampa, a couple in Orlando, five in Sarasota, five in 
Jacksonville, and one in Miami. All were in or close to metropolitan areas. 
Trial-Matching Resources 
Web-based search engines enable those with access to computers to seek specific clinical trials 
with descriptive overviews, a list of sites that offer them, and contact information for further 
information.  One of the most thorough, reputable and user-friendly sites is the National Cancer 
Institute’s trial-search site that finds trials by location, type, treatment, drug, keywords, phase, 
and sponsor at http://www.cancer.gov/clinicaltrials/search.  
Especially useful for Floridians is the trial-matching tool 
http://www.floridacancertrials.com/en/, powered by Emerging Med,  supported by Grant Award 
D1BIT10963-01-00 from the Office of Health Information Technology, Health Resources and 
Services Administration, DHHS, and designed to allow persons to enter details about their type 
of cancer and be matched according to a high level of detail to potentially suitable clinical trials 
statewide. 
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A Theoretical Approach to Framing Clinical Trial Enrollment 
Consolidated Framework for Implementation Research (CFIR) 
The theoretical basis for my gynecologic-oncology systems-based research is the 
Consolidated Framework for Implementation research (CFIR).  CFIR includes the elements of 
intervention characteristics, the outer setting, the inner setting, characteristics of individuals, and 
the process (Damschroder et al., 2009), as shown in Figure 2.5.  Among the intervention 
characteristics are its source, evidence strength and quality, relative advantage, adaptability, 
trial-ability, complexity, design quality and packaging, and cost.  Note that the intervention in this 
application is enrollment in a clinical trial. It is important to understand that the intervention box 
on the left depicts enrollment as it currently exists, which is why it is shown as a detached 
rectangle; the detachment is synonymous to the presumption that 
 
Figure 2.5. CFIR Domains: Outer Setting, Inner Setting, Intervention, Process (adapted from 
Damschroder L, Aron D, Keith R, Alexander J, Lowery J – Fostering implementation of Health 
Services Research Findings into Practice)	
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the intervention, enrollment in ovarian cancer clinical trials, with better understanding necessary 
and sufficient factors as well as facilitators and barriers, may be improved through informed 
interventions that target the outer and inner settings and enrollment process. Thus the 
“attached” rectangle on the right indicates the adapted enrollment process after informed efforts 
have targeted the outer and inner settings, including individuals, and the overall process.  
Applying CFIR to Ovarian Cancer Clinical Trials 
The outer setting for CFIR is shown in Table 2.5; for this study the outer setting will be 
comprised of gynecologic-oncology departments within institutions and community-based 
practice settings in Florida. The inner setting (see Tables 2.6 to 2.9) encompasses structural 
characteristics, e.g. of an institution or departments, networks and communication, culture, 
characteristics of the climate for implementation, and readiness by leaders, access to resources 
and information and knowledge.  
  
Table 2.5. Outer Setting 
 
Public Resources 	
• Does your practice have a website? (Q22) Yes or No 
• Does your practice have clinical trial resources for patients?   
(Q47) Yes or No	
• Does your practice provide patient education literature on 
clinical trials? (Q31)	 Yes or No	
Professional Resource 	
• Does your practice educate staff about clinical trials? (Q34) Yes or No	
• Does your practice have resources to help you answer 
questions about clinical trials? (Q43) Yes or No	
Cosmopolitanism 	
• The size of the community you serve rural / small town OR 
city / major urban area	
External Incentives 	
• Does your practice ever appear in local publications such as a 
newspaper? (Q24) Yes or No	
• Has your practice been featured or promoted on local TV or 
radio? (Q25) Yes or No	
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Table 2.6. Inner Setting: Structural Characteristics for Practice Nurses	
	
 
Table 2.7. Inner Setting: Networks/Communication Culture for Practice Nurses	
	
When ovarian cancer clinical trials are discussed with patients, who is most likely 
to bring up the topic? (Q28) 
	
• The patient Yes or No 
• The physician Yes or No	
• Nurse practitioner Primary care nurse Yes or No	
• Research nurse Yes or No	
Does your practice have a plan for presenting the option of a clinical trial to 
women with ovarian cancer? (Q27) Yes or No	
Does your practice provide ovarian cancer patient education on any of the 
following? (Q23) 
	
• Treatment Yes or No	
• Symptoms Yes or No	
• Clinical trials Yes or No	
• Support groups Yes or No	
Which of the following should be able to talk about ovarian cancer clinical trials 
with patients? (Q29) 
	
• Physicians Yes or No	
• Nurse practitioners Yes or No	
• Primary care nurses Yes or No	
• Research nurses Yes or No	
Table 2.7 continues on next page. 
Total Medical Oncologists (Q6) Gynecologic Oncologists (Q7) / nurse 
practitioners (Q8) / primary nurses (Q9)/ research nurses on staff (Q10).   
Numeric 
values 
With what hospital(s) is your practice linked for surgeries and treatment? (Q21) Text write-in 
Do you have an on-site infusion center? (Q20)  Yes or No 
Race of ovarian cancer patients with stage III/IV disease treated on site in the 
last 12 months (Q18 - 19) 
% white 
% black 
% Asian 
Ethnicity of ovarian cancer patients with stage III/IV disease treated on site in the 
last 12 months  
% Hispanic 
% nonHispanic 
Values 
About how many women with ovarian cancer were seen in your practice in 
2013? (Q13) Values 
About how many women with ovarian cancer were enrolled in clinical trials at 
your site in 2013? (Q14) Values 
About how many women with ovarian cancer were referred to another practice 
for a clinical trial in 2013? (Q15) Values 
Does your practice have on-site clinical trials for ovarian cancer patients? (Q11) Yes or No 
Does your practice ever refer ovarian cancer patients to other sites for the 
purpose of participating in a clinical trial? (Q12) Yes or No 
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Table 2.7 (continued)	
Do you ever use clinical trial websites? (Q32) Yes or No	
Does your team have a plan for offering clinical trials to women with recurrent or 
persistent ovarian cancer? (Q45) Yes or No	
Does your team discuss ovarian cancer clinical trials during team meetings? 
(Q46) Yes or No	
If a patient asks about clinical trials, is she referred to the doctor for further 
discussion? (Q48) Yes or No	
If you don’t have a clinical trial for a woman with ovarian cancer who wants one, 
do you have a plan to help her find one? (Q49) Yes or No	
 
Characteristics of individuals within the inner setting of medical or gynecologic oncology  
departments within institutions and community-based practice settings would include knowledge 
and beliefs about the practice or intervention, in this case offering a clinical trial, self-efficacy, 
individual stage of change, one’s identification with an organization, and additional personal 
attributes. Key persons within medical and gynecologic oncology departments within institutions 
and community-based practice settings would include medical and gynecologic oncologists, 
PAs and ARNPs, research nurses, and nurses who provide outpatient and inpatient care for 
women with ovarian cancer.  
 
Table 2.8. Inner Setting: Implementation, Incentives, Learning Climate for Practice Nurses 
	
Do you think ovarian cancer clinical trials are a priority at your facility? (Q30) Yes or No 
Do you have computers in the waiting area for patients’ use? (Q33) Yes or No 
Do you ever use clinical trial websites? (Q32) Yes or No 
Does your practice provide patient education literature on clinical trials?  (Q31) Yes or No 
Does your practice educate staff about clinical trials? (Q34) Yes or No 
Does your practice have resources to help you answer questions about clinical 
trials? (Q43) Yes or No 
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Table 2.9. Inner Setting: Practice Nurses	
	
 
Process elements include planning, engaging one’s opinion leaders and champions, executing, 
and reflecting and evaluating (Damschroder et al., 2009). For indicators associated with process 
elements, see Table 2.10. 
Table 2.10. Process: Planning, Engaging, Executing for Practice Nurses	
	
Does your team have a plan for offering clinical trials to women with recurrent or 
persistent ovarian cancer? (Q45) Yes or No 
Does your practice educate staff about clinical trials? (Q34) Yes or No 
Does your practice provide patient education literature on clinical trials?  (Q31) Yes or No 
Does your practice have resources to help you answer questions about clinical 
trials? (Q43) Yes or No 
If a patient asks about clinical trials, is she referred to the doctor for further 
discussion? (Q48) Yes or No 
If you don’t have a clinical trial for a woman with ovarian cancer who seeks a trial, 
do you have a plan to find her one? (Q49) Yes or No 
 
In addition to demographics that will be provided in a subsequent chapter, women with ovarian 
cancer were asked one behavior question (have you ever been in a clinical trial?) and an 
intention question (are you likely to agree to participate if offered a clinical trial?). Questions 
related to the theoretical inner setting were also asked of the participants who were women with 
ovarian cancer (Tables 2.11 through 2.14). 
  
Knowledge 
Do you believe that health insurance covers standard-of-care costs in a clinical 
trial? (Q35) Yes or No 
Do you think the ACA will be helpful in covering CT costs? (Q36) Yes or No 
Do you want to know more about clinical trials? (Q44) Yes or No 
Beliefs 
Should ovarian cancer patients be informed about clinical trials as early as 
possible after being diagnosed? (Q37) Yes or No 
Should clinical trials be the last resort after all known treatments fail? (Q38) Yes or No 
Self-Efficacy 
Are you comfortable answering patients’ questions about clinical trials? (Q41) Yes or No 
Do you feel well informed when patients ask about clinical trials? (Q42) Yes or No 
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Table 2.11. Inner Setting: Structural Characteristics for Women with Ovarian Cancer 
 
 
Table 2.12. Inner Setting: Networks/Communication Culture for Women with Ovarian Cancer 
Which of the following providers of care have ever suggested you think about a 
clinical trial? Check all that apply (Q13) 
 
• Oncologist Yes or No 
• Nurse practitioner Yes or No 
• Research nurse  Yes or No 
• Primary care nurse Yes or No 
• Family member Yes or No 
• Friend Yes or No 
• No one Yes or No 
If you wanted a clinical trial that your practice didn’t offer, do you think your 
doctor would help you find a facility that offers the trial? (Q22) Yes or No 
Do you think website information for any of the following topics is helpful? Check 
all that apply (Q28) 
 
• Treatment Yes or No 
• Symptoms Yes or No 
• Clinical trials Yes or No 
• Support groups Yes or No 
 
 
Table 2.13. Inner Setting: Implementation, Incentives, Learning Climate for Women with 
Ovarian Cancer 
 
  Has your doctor or nurse ever discussed clinical trials with you? (Q8) Yes or No 
Does your oncologist offer clinical trials? (Q14) Yes or No 
Have you ever seen patient education literature on clinical trials in your doctor’s 
office? (Q17) Yes or No 
Does your oncologist have a website? (Q26) Yes or No 
If your oncologist had a website that helped you find matching clinical trials, 
would you use it? (Q27) 
Yes or No 
(why) 
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Table 2.14. Inner Setting: Women with Ovarian Cancer 
 
 
   
Knowledge 
Do you believe that health insurance covers standard-of-care costs in a clinical 
trial? (Q29) Yes or No 
Do you think the ACA will be helpful in covering CT costs? (Q30) Yes or No 
If your doctor or nurse mentions clinical trials, do you want to know more? (Q15) Yes or No 
Beliefs 
Do you think it makes sense to consider a clinical trial right after you are diagnosed 
with cancer? (Q18) Yes or No 
Do you think clinical trials are an option to be considered only if other treatments 
stop working? (Q19) Yes or No 
Self-Efficacy 
Are you comfortable answering bringing up the subject of clinical trials to your 
doctor? (Q16) Yes or No 
If a clinical trial required extra visits, would that stop you from participating? (Q23) Yes or No 
If a clinical trial meant traveling an extra 30 miles each visit, would that stop you 
from participating? (Q24) Yes or No 
Would your family be supportive if you were in a clinical trial? (Q25) Yes or No 
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CHAPTER THREE:  METHODOLOGY 
Purpose of the Study 
The primary purpose of this multiple case study was to identify the necessary and/or 
sufficient factors that are instrumental in making clinical trials accessible to women with 
persistent or recurrent ovarian cancer in the state of Florida. The secondary purpose was to 
identify facilitators and barriers within the gynecologic oncology practice setting that, in the 
longer term, may be used to inform targeted interventions to improve trial access and accrual.   
Research Questions 
This multiple case study attempted to answer the following research questions: 
1. What necessary and/or sufficient factors, based on Qualitative Comparative 
Analysis (QCA)(Ragin, 1989), within the gynecologic oncology practice network 
in Florida, enable a woman with recurrent or persistent ovarian cancer to enroll in 
a clinical trial? 
2. What barriers and facilitators exist with regard to enrolling women with ovarian 
cancer in clinical trials? 
To answer the preceding research questions, I proposed a multiple case study using 
mixed methods to determine necessary and/or sufficient factors, as well as barriers and 
facilitators, to enrollment by women with recurrent or persistent ovarian cancer in clinical trials in 
Florida.  The theoretical framework for the study is the Consolidated Framework for 
Implementation Research (CFIR), which was explained in chapter two. 
Rationale for the Approach 
Mixed methods have multiple purposes in research that can include triangulation, 
complementarity, initiation, development, and expansion (Greene, Caracelli, & Graham, 1989). 
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In addition to multiple purposes for using mixed methods, there are multiple strategies for 
combining them, and the logical approach in this multiple case study was to use a survey that 
would provide quantitative and qualitative data. Quantitative findings would be interpreted via 
Qualitative Comparative Analysis (QCA, explained in a subsequent section of the chapter), and 
the answers to open-ended questions would provide qualitative data to explain quantitative 
findings and triangulate, or show whether there is convergence between/among cases with 
similar findings on various constructs in the CFIR theoretical framework (Ulin, Waszak, & 
Pfannenschmidt, 1996). QCA, notably, is useful for case studies for which little preexisting 
research has been done, and when there is a relatively small number of cases for which the 
researcher seeks clarification of causal patterns (Donnelly & Wiechula, 2013).  QCA enables 
cross-case comparisons that show what conditions are “sufficient” for an outcome of interest 
(Ragin, 1989).  In this case, the outcome of interest was enrollment in a clinical trial.  QCA was 
thus used to determine variables associated with high and low (or no) enrollment in clinical trials 
by women with ovarian cancer and by nurses affiliated with gynecologic or medical oncology 
practices that see women with recurrent or persistent ovarian cancer in Florida.   
The outcome of interest is enrollment in clinical trials by women with ovarian cancer. The 
influents of enrollment were sought for two populations: women with ovarian cancer and nurses 
in medical or gynecologic oncology practices. Both specialties were included because there are 
many more medical than gynecologic oncologists, and many women with ovarian cancer opt to 
have chemotherapy closer to home, administered by a medical oncologist. Further, some 
medical oncologists offer clinical trials or refer their patients to gynecologic oncologists for 
clinical trials. The influents were considered within the five domains of the Consolidated 
Framework for Implementation Research (CFIR) in Table 3.1 on the following page. 
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Table 3.1. Five Domains of the Consolidated Framework for Implementation Research (CFIR) 
Domain Description and Examples of Associated Constructs 
Intervention Characteristics of the intervention such as complexity, cost, and 
relative advantage. 
Inner Setting Structural, political, and cultural contexts through which 
implementation proceeds: organizational structure, social architecture, 
communication/networks, and implementation climate and readiness. 
Outer Setting Economic, political, and social context in which an organization 
resides. Includes the extent to which the organization has an accurate 
knowledge of patient needs, billing and reimbursement, funding 
constraints, and ties to external organizations. 
Individuals Involved Individuals in the inner or outer setting can promote the 
implementation process and alter program effectiveness via their 
actions, which are influenced by attitudes and motivations. 
Implementation 
Process 
Actions that lead to implementation, protocol and procedures. 
 
The steps for performing QCA are listed in Table 3.2. 
 
Table 3.2. Steps Used to Perform the Crisp Set Qualitative Comparative Analysis* 
1. Define and operationalize the outcome 
of interest, and assign dichotomous 
scores for the outcome. 
Outcome is enrollment in a clinical trial, defined as 
consenting to participate in a study. Whether a 
woman completed the clinical trial was not a 
condition of interest in this study. The outcome of 
interest was operationalized by survey questions 
discussed in earlier sections. 
Enrollment was 1 for yes and 0 for no. 
2. Select Cases All 20 patients who responded were included. One 
of 7 nurses who responded did not answer all the 
questions and thus had to be excluded.  
3. Identify key conditions, use 
dichotomous score for each condition and 
create a data matrix of scores for 
conditions. 
Many questions were asked of nurses and patients 
for the purpose of gaining quantitative and 
qualitative information on the cases that would help 
inform conditions within the five domains of CFIR. It 
was anticipated that most of the information from a 
case study would pertain to intervention, inner 
setting, and the individuals involved. Most 
questions were dichotomous “yes or no,” 
supplemented by several open-ended questions to 
gather qualitative data. Dichotomous questions 
were coded as 1 for yes (present) and 0 for no 
(absent). A data matrix (Table 4.38) was created 
for the outcome and key conditions.   
Table 3.2 continues on next page. 
	
37	
	
Table 3.2 (continued)	
4. Determine the analyses. 
 
Conditions for enrollment in clinical trials were 
analyzed for sufficiency solely or in combination 
with other factors. A necessary factor would be the 
existence of a clinical trial, but that in and of itself 
would not necessarily be sufficient to enroll a 
participant 
5. Create a truth table. fsQCA 2,0 was used to create a truth table to show 
possible configurations of selected conditions 
(Table 4.39). 
6. Analyze the truth table and resolve 
contradictions. 
Table 4.39 shows those enrolled versus those 
never enrolled in a clinical trial, juxtaposed with the 
conditions of interest. 
7. Use software to a find solutions by 
making multiple comparisons of case 
configurations in the truth table. 
Use fsQCA 2.0 to perform a standard analysis to 
identify conditions associated with enrollment 
versus nonenrollment. fsQCA uses the Quine-
McCluskey algorithm (based on Boolean 
simplification) to make multiple comparisons of 
case configurations in the truth table. High 
consistency scores are used to choose prime 
implicants. The software then generates a 
complex, intermediate, and parsimonious solution.  
8. Find out of the influence of conditions 
has symmetry. 
Compare conditions to see if presence and 
absence conform to those with and without the 
desired outcome (enrollment in a clinical trial). 
9. Assess consistency and coverage of 
the solutions. 
Overall solution consistencies should be 1 (present 
for all cases with the desired outcome). 
10. Interpret solutions and create causal 
models. 
Association with an outcome does not assume that 
conditions caused the outcome. Solutions can be 
applied to frameworks to help develop models of 
causality. 
*Note that this table is guided by steps published in 2013 (Cragun et al., 2013). 
	
Potential Significance 
While there is speculation as to the factors associated with clinical trial enrollment 
patterns by women with recurrent or persistent ovarian cancer, to date there are no studies that 
systematically measure necessary and/or sufficient factors associated with trial enrollment in 
Florida, looking at both patients’ and providers’ perceptions.  This study was intended to identify 
necessary and/or sufficient factors associated with trial enrollment as well as barriers and 
facilitators within Florida’s gynecologic oncology institutional and community practice settings. 
Findings could be used to inform subsequent research and interventions for more equitable 
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statewide access to resources in accordance with the NCCN guideline on clinical trial options 
for women with recurrent or persistent ovarian cancer in Florida. 
The Study Populations 
The study population was comprised of women who were diagnosed with ovarian cancer 
and nurses in medical or gynecologic oncology practices, not all of which offer clinical trials on 
site. Some practitioners, however, may be part of a collaborative or referral network for the 
purpose of helping women with ovarian cancer enroll in clinical trials.  The inclusion of both 
specialties was necessary because many women with ovarian cancer opt to have adjuvant 
chemotherapy close to home, administered by a medical oncologist. The low number of 
gynecologic oncologists compared to medical oncologists compared to gynecologic oncologists 
would have made it difficult or impossible to find 20 unique practices. The goal was to determine 
clinical trial enrollments and/or referrals in the 20 unique practices—it would have been 
impossible to find that many gynecologic oncology practices. 
Study Schema and Proposed Timeline 
The survey included demographic data, tied to the constructs, as well as potentially necessary 
and/or sufficient factors related to enrollment in clinical trials. The proposed timeline for this study 
was one year, with possible delays anticipated with regard to regulatory processes associated with 
the scientific review committee at Moffitt Cancer Center and the University of South Florida 
institutional review board, as well as unanticipated recruitment challenges. Regarding recruitment, it 
was hoped that an incentive would enable timely recruitment and completion of the survey by 20 
women with ovarian cancer and by 20 nurses in medical or gynecologic oncology practices. 
The following study materials were created for IRB review and approval: 
1. Study protocol for submission to the IRB along with the following: 
2. A print version of the on-line nursing and patient surveys created in Qualtrics Invitation 
letter (1) and email (2) reminders to increase responses using the Dillman method 
adapted for online surveys, which is the use of mixed modes (mail and email for 
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example), shorter time between contacts, and a diminished overall length the reminder 
period (Dillman, 2000; Parsons, 2007). The letters described the purpose of the study 
and invited them to take an online survey, for which they would receive a $20 incentive 
for completion of the survey. See the appendices for the letter and follow-up emails sent 
to nurses and to patients. 
 
Figure 3.1. Study Schema 
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Recruitment  
Recruitment of Women with Ovarian Cancer 
Moffitt Cancer Center launched the Total Cancer Care (TCC) protocol in 2006, in which every 
patient at Moffitt is invited to provide written informed consent to allow their biospecimens and 
clinical data to be used for ongoing research, and to agree to be contacted for opportunities for 
voluntary participation in emerging studies that may relate to their specific cancer 
diagnosis/predisposition and thus potentially be beneficial to them or others. Using the TCC 
protocol, the following data (Table 3.3) was requested on July 17, 2014 for all women over age 
18, diagnosed with stage III/IV ovarian cancer, who presented to Moffitt Cancer Center between 
January 1, 2010, and June 30, 2014, who were still living on the data-request submission date. 
On October 1, 2014, TCC provided the requested data for 118 cases. It was hoped that a chart 
review would reveal at least 20 unique referring practices, which would comprise the target 
mailing to practice nurses. Notably, the data provided by TCC did not include names of four 
women with ovarian cancer known to the investigator from participation in a different study, and 
those patients were added to the list. Patients for whom a referring practitioner’s name was 
available were selected to receive the initial invitation letter. The chart review for 20 unique 
practices yielded 60 cases with a unique referring provider, which was the starting point for 
patient and nurse recruitment.  
Table 3.3. Variables Requested from TCC on 7/17/14 
Medical Record Number Date of Diagnosis 
TCC ID number Survival time in months 
Histology code Treatment summary 
Histology behavior Age at diagnosis 
First & last name Current age 
Primary site Marital status 
Class of case Date of first contact 
TNM stage Telephone number 
Date of last contact Postal code 
Race County 
Ethnicity Street address 
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TCC query results for patients. The intention was to include patients for whom the 
referring physician’s name and address were available, to see if responses of both patients and 
practice nurses would be congruent, but with a very low yield of responses from the 20 
practices, that strategy was not possible. Moreover, the TCC list omitted several women who fit 
the inclusion criteria whom the PI knew from prior study involvement.  A mailing and follow-up 
calls to 31 women who were on the TCC list led to 12 consented women who completed the 
online survey (Table 3.4). Needing 7 more participants, the PI contacted 4 women who were not 
listed in the TCC data output but who fit the inclusion criteria; all 4 women were consented and 
completed surveys. Three more women were needed, thus the PI contacted a liaison with the 
nonprofit ovarian cancer support group Ovacome, which yielded 4 more women who provided 
written informed consent and completed surveys. The recruitment sources for the sample of 
women with ovarian cancer are shown in Table 3.4. 
Table 3.4. The recruitment sources of women with ovarian cancer who were consented and 
provided completed surveys (N=20). 
 
Source of consented participants N % 
TCC data output 12 60% 
Eligible Moffitt patients not in TCC output 4 20% 
Ovacome referrals 4 20% 
Total 20 100% 
 
Letters with enclosed consent forms and prepaid addressed return envelopes were 
prepared and posted on August 19, 2014, to the 60 patients for whom referring provider 
information was available. By September 23, 2014, 12 women had returned signed informed 
consent forms, and by January 15, 2015, all 12 had completed the survey.  Follow-up calls were 
made to those who did not respond, and messages were left only if there was an opportunity; 
follow-up calls did not influence any who did not initially provide informed consent. At that point, 
with follow-up calls failing to increase the number of consented participants, the four women that 
were not on the TCC data output file were contacted, via letter and consent form mailed 
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February 2, 2015, and all had consented by February 14 and completed the survey by February 
18, 2015. With the additional four participants, the sample total was 16, and four more women 
were contacted by using the investigator’s connection with Ovacome,  an all-volunteer, 
501(c)(3) nonprofit organization founded in 1999 to provide support and education to women in 
the Tampa Bay area who are diagnosed with ovarian and other gynecologic cancers. The 
Director of Ovacome provided the names of six women, to whom letters with enclosed consent 
forms and return envelopes were mailed on March 10, 2015. By March 23, four had returned 
signed consent forms, and by March 28, 2015, all four had completed the survey, yielding a total 
of 20 enrolled women who had completed surveys. The time it took from the initial mailing on 
August 19, 2014, to having twenty completed surveys on March 28, 2015, was thus 222 days, 
or 31 weeks and 5 days.  
Recruitment of Nurses 
The goal for nurse recruitment was to have 20 nurses, each from a different practice, 
complete the survey, and to have a spread of nurses that included one from Moffitt and one 
from TGH, with the balance from solo gynecologic or medical oncology practices throughout the 
Tampa Bay area. The differing sites and practice types were desired to provide a realistic array 
of variables across practices that treat women with ovarian cancer. The purpose was not to 
recruit multiple nurses from one site, particularly from Moffitt Cancer Center, where clinical 
research is integral to the culture. To do so would have introduced bias. 
TCC query results for practice nurses. On July 17, 2014, a request for data from the 
Total Cancer Care (TCC) protocol was made for all women over age 18, diagnosed with stage 
III/IV ovarian cancer, who presented to Moffitt Cancer Center between January 1, 2010, and 
June 30, 2014, who were alive as of the data-request submission date. The query yielded a 
data file that was provided October 1, 2014, for 118 cases. The next task was to identify those 
for whom the name of a referring provider was included, and 60 cases (51%) included unique 
names of referring physicians. A Google search was used to identify practice addresses for 
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mailings to the provider’s primary nurse, which reduced the number of cases to 20. Ultimately, 
after contacting the 20 practices using the Dillman method (letter followed by telephone calls), 
only two surveys were completed by nurses.  
The starting point for locating referring providers was the list of 60 ovarian cancer 
patients for whom chart reviews yielded specific referral information. Each referring provider 
name was “Googled” for a practice address, and twenty referring doctors’ names and addresses 
were located. Letters and envelopes were addressed to the attention of “The Primary Nurse for 
Dr. ‘Doe’” and mailed on October 20, 2014; consent was part of the on-line survey, and the 
letter requested a telephone call so that the investigator could obtain the nurse’s email address 
and provide the link to the survey. In other words, the letters to nurses were depersonalized 
because the investigator did not have a name or an email address. Getting those identifiers 
would have to occur as a result of the nurse receiving the depersonalized letter and calling the 
investigator to provide contact information consisting of email address and telephone number 
and extension. There were no responses within two weeks, thus follow-up calls began the first 
week of November; calls were answered by an operator or receptionist who would ask if the 
caller was a patient. In one instance, upon explaining the purpose of the call, the receptionist 
said that any kind of survey would have to be approved by the business manager and that the 
process could take months. Only one follow-up call reached a nurse, who expressed that she 
was extremely busy and wrote down the survey link and said she would try to get to it when she 
had time. A call-back two weeks later produced the same statement; ultimately, the survey was 
never completed by that particular nurse. The nurses from Moffitt and Tampa General Hospital 
were known to the investigator, and both nurses completed the survey within two weeks of 
being asked. An email requesting nursing leads at other oncology practice sites was sent to six 
gynecologic oncology nurses and two gynecologic oncology nurse practitioners and one 
gynecologic oncology physician assistant on December 8, 2014. The primary nurses stated that 
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they did not know nurses at other practice sites in the Tampa Bay area, and one nurse 
practitioner suggested a closer connection to the University of South Florida (USF) College of 
Nursing. The low response rate for nurses led to consultation with two nursing professors. One 
professor sent email requests to several nurses, which precipitated five additional surveys, one 
of which could not be used because only two-thirds of it was completed, bringing the total to six 
completed surveys by December 17, 2014. The next strategy, which was approved by Moffitt’s 
Science Review Committee and the USF IRB on May 5, 2015, was to include an announcement 
in the USF College of Nursing newsletter, inviting nurses to follow the link to the survey and 
receive a twenty dollar incentive upon completion. This strategy yielded just one additional 
survey, for a total of seven surveys completed by practices nurses as of June 18, 2015. The low 
response rate by practice nurses will be discussed in the results section. 
Method of Survey Analysis 
The analytic method for the quantitative items in the survey was Qualitative Comparative 
Analysis (QCA), which was selected because it offers a practical approach to understanding 
complex real-world situations. QCA was created for case study research to derive solutions that 
include a list of factors that, if absent or present, are uniquely associated with an outcome 
(Ragin, 1989).  QCA allows the researcher to build models by determining which conditions, in 
combination, are necessary and/or sufficient for a particular outcome.  QCA is particularly useful 
in situations involving case studies with little preexisting research, and in which there is a 
relatively small number of cases suited to dichotomous variables, and when the researcher 
seeks to understand or interpret causal patterns; QCA findings are presented using Venn 
diagrams and truth tables, must be directly related to the cases being studied (e.g., the 
institutions and practice settings), and should explain the Boolean notation in conjunction with 
the resulting narrative (Donnelly & Wiechula, 2013; Schneider & Wagemann, 2010).  
Although qualitative and quantitative research tend to be used comparatively (Bazeley, 
2009) and are not usually combined within one procedure (Ragin, 1989), QCA has not only 
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been used successfully in case study research in the realm of political science, but has recently 
been used to determine factors related to variable outcomes across fifteen institutions that 
provide universal tumor screening programs to identify patients with Lynch syndrome, which is 
the predominant cause of hereditary colorectal cancer (Cragun et al., 2014; Cragun et al., 
2013). Cragun and colleagues (Cragun et al., 2014), in examining the use of QCA, noted the 
method’s significance in assessing the value of solutions and in building models by deriving 
components of necessity and/or sufficiency for a desired result.  Donnelly and colleagues (2013) 
used QCA to study the role of clinical placement, nursing education and patient outcomes in a 
case study (n=16) that involved a questionnaire and interviews.   
Using Crisp versus Fuzzy Set Data 
QCA, applying set theory to seek a combination of causal conditions, has two variations:  
crisp set, which is being present or not (csQCA), and fuzzy set, which has a range of “gray” 
options that exceed the dichotomous on or off options of crisp-set QCA (fsQCA) (Rihoux, 2006).  
Strong speculation is that many of the community-based practices do not have clinical trial 
resources, but this has not been systematically documented. With documentation, along with a 
dimension that probes for reasons and identifies barriers and facilitators, proposals for 
interventions can be created with requests for funding and support to increase clinical trial 
enrollment access for women with recurrent or persistent ovarian cancer throughout Florida. If 
speculation is accurate, which, especially considering the distribution of gynecologic oncology 
practitioners in conjunction with the fact that ovarian cancer is one of the more rare, albeit 
deadly cancers, it is likely that many community-based practices do not have the resources to 
offer clinical trials to patients with persistent or recurrent disease. With that consideration in 
mind, most of the questions that were asked, except for demographics, are conditions that are 
either present or not, making the crisp-set variant preferable for this study. 
In questions for which numbers are desired, answers can be dichotomized by using two 
categories of numeric ranges, for example having 0-3 or 4-6 gynecologic oncologists at a 
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treatment center. By using QCA to develop survey questions, one may identify factors that are 
necessary and/or sufficient for women with recurrent/persistent ovarian cancer to be enrolled in 
clinical trials at various facilities throughout the state of Florida.  A cause is considered 
necessary if it is required for an outcome; a cause is considered sufficient if it can produce an 
outcome by itself (Ragin, 2008).   
Survey of Nurses in Gynecologic or Medical Oncology Practices 
Nurse respondents were put into two groups: 
• Practices that enrolled at least one ovarian cancer patient in an on-site clinical trial or referred 
her to another site for a clinical trial in the last 12 months. 
• Practices that neither enrolled nor referred an ovarian cancer patient to another site for a 
clinical trial within the last 12 months. 
Source of Data 
Data comes from the on-line survey completed by a primary care or research nurse who 
enrolls in or refers women with ovarian cancer to clinical trials. Most of the data, except for 
several write-in demographic questions, is quantitative, blending nominal demographic data with 
dichotomous data structured for Qualitative Comparative Analysis (QCA), as described in the 
preceding section and is being now explained in terms of its application to the preceding 
dependent variable: high or low enrollment in ovarian-cancer clinical trials.  QCA survey 
questions have dichotomous choices—presence or absence, 1 or 0, except for a few exceptions 
in which numeric ranges are broken into two spans. The fsQCA2.0 software, upon data entry, 
will analyze which independent variables in the survey, alone and in combination, are present 
for each of the three conditions of the dependent variable, enrollment (high, low, mid-range). 
The software generates a truth table, each row of which is an independent variable.  
Survey Design 
On-line survey development using Qualtrics. Survey design requires care in writing 
succinct, clearly worded questions that avoid jargon or abbreviations, ambiguity, emotionality, 
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double-barreled and leading questions, and complexity that disincentivizes the respondent 
(Neuman, 2006). Because some of the survey questions are related to practice demographics, it 
was important to clarify that the survey could be saved and returned to later in case answering a 
question required discussion with another team member.   
Questions for demographics preceded questions associated with the theoretical 
constructs of the CFIR domains, and were asked of two populations:  nurses in medical or 
gynecologic oncology practices, and women diagnosed with ovarian cancer. Refer to the 
appendices for the surveys, which were provided via email with a link to an on-line survey 
executed in the Qualtrics platform. 
Reliability and validity. Content validity was reviewed by asking research nurses if key 
factors were missing, if irrelevant factors existed and should thus be deleted, and if wording was 
accurate and succinct. No other measure of this type exists, and the variables were linked to 
theoretical constructs. With regard to reliability, a test-retest pilot was conducted on several 
research nurses before launching the final survey. The same procedure was done with the 
survey for patients, using a subset of women with ovarian cancer to make sure the survey 
wording was accurate and straightforward. 
Issues Related to Self-Reported Survey Research 
Self-reported survey data always has limitations related to recall, cognitive skills, 
individual commitment, environmental distractors, and bias (Streiner & Norman, 2008). 
Inference and estimation. The risk with inference and estimation is over- or 
underestimating and missing a rare exception that may have occurred, especially with the use 
of crisp-set QCA, that imposes dichotomous response choices that will challenge the research 
nurse to recall actual events and categorize them into absolute values such as all or none 
categories or broad ranges. Depending on the question, this could be easy or difficult, but for 
patterns related to ovarian cancer clinical trial practice procedures, since ovarian cancer is a 
rare cancer, this should not be overly challenging. Moreover, ovarian cancer clinical trials, 
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although available at some of the larger centers, per an on-line search that was done recently, 
did not appear to be prevalent throughout the state of Florida. 
Social desirability. There was the risk that the nurse who completed the survey would 
be under pressure to make the practice “look good” in terms of enrollments and offers of clinical 
trials to patients. To achieve a positive image, she or he may thus be tempted to exaggerate 
responses in the positive direction to give the impression that more trial offers are made to 
women with persistent or recurrent ovarian cancer than are the case. In an effort to reduce this 
risk, an introductory plea for accuracy was made so that findings could accurately inform future 
interventions that might provide useful tools and build collaborative networks. In every 
dimension of the study, the importance of honesty, accuracy, and integrity was emphasized. 
Sampling and recruitment. Sampling started with a query to the Total Cancer Care 
protocol to release a data output file; referring practices were selected from that file for 
generating letters to practice nurses. The TCC data file was to include all women over age 18, 
diagnosed with stage III/IV ovarian cancer, who presented to Moffitt Cancer Center between 
January 1, 2010, and June 30, 2014, who were still living on the data-request submission date. 
Upon receiving the data file, the investigator would conduct chart reviews to find cases for 
whom the name of a referring provider was available. It was hoped that the incentive of a $20 
gift card would achieve a 60% rate of response, or survey completion by 36 nurses. 
Survey Data Analysis 
This is a multiple case study with a small sample size, which is why QCA is an 
appropriate analytic method.  The quantitative survey data would be analyzed using the 
fs/QCA2.0 software, downloaded at no cost from a link made available by Dr. Charles Ragin, 
who explained that this software package can be used for both crisp and fuzzy set analysis 
(Personal communication via email with Charles Ragin on Sunday, January 5, 2013). The QCA 
method was discussed in the preceding section.  
The following steps were undertaken; 2 through 7 are adapted from Cragun (2013): 
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1. Create a codebook of all independent variables, separating demographic data from 
dichotomous QCA data. 
2. Create a QCA data matrix with membership scores for the outcome (enrollments) and 
key conditions per case (practice). 
3. Determine whether a necessity analysis is needed. If not, conduct only a sufficiency 
analysis. 
4. Using fsQCA2.0, create a truth table showing all possible configurations of selected 
conditions. 
5. To resolve any contradictions that may exist, add an additional condition to create a 
revised truth table. 
6. Use fsQCA2.0 to conduct a “Standard Analysis” to detect conditions associated with 
HPEs (high patient enrollments), generating three solutions:  complex, parsimonious, 
and intermediate. 
7. Determine if conditions associated with HPEs are the same as those with low (~HPE) 
by repeating steps 3 to 6 and using ~HPE as the outcome. 
The qualitative data from the open-ended survey questions would be analyzed by 
identifying themes for the purpose of explaining and better understanding the quantitative 
findings and will be found along with descriptive statistics and QCA findings in the results 
section. 
Anticipated Problems and Plans for Troubleshooting 
     This multiple case study included hospital- and community-based gynecologic oncology 
practices. Community-based practices linked to small hospitals are presumed to have less 
resources than practices linked to large metropolitan hospitals. Those differences were to be 
explored with the inclusion of several survey questions about practice resources, e.g. staff 
receives training, a practice website and/or clinical trial search tool exists, patient education 
materials on clinical trials are available in the practice. 
50	
	
      A challenge at the beginning of the study was anticipated with regard to gaining the 
attention of the nurses asked to complete the online survey. It was hoped that the incentive 
would be sufficient, and presumed that the greatest hurdle would be reaching the primary 
practice nurse with the invitation to participate.  It was also hoped that an introductory letter 
followed by a telephone call would yield a nurse’s name, telephone number, and email address. 
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CHAPTER FOUR: RESULTS 
Descriptive Statistics for Participating Practice Nurses and Women with Ovarian Cancer 
Practice Nurses 
Eleven nurses began the survey but four stopped after they answered question number eight, 
which asked for the number of nurse practitioners in the clinic; question nine asked how many 
primary care nurses were in their clinic. Seven practice nurses completed the entire survey; 
one, a research nurse, was from Moffitt Cancer Center, one was from Tampa General Hospital, 
and five were with Florida Cancer Specialists at five different practice sites, in Tampa, Hudson, 
Largo, Venice, and Clearwater. More than half of the practices reported having at least one 
research nurse in the clinic, and offering on-site ovarian cancer clinical trials (see Table 4.1). 
Table 4.1. Practice nurses who reported having a research nurse in their clinic and having on-
site clinical trials for ovarian cancer patients? 
 
Yes 4 57% 
No 3 43% 
Total 7 100% 
Variance: 0.29; Standard Deviation: 0.53 
 
Interestingly, although four practices reported having on-site clinical trials for ovarian cancer 
patients, only one nurse reported enrolling a woman with ovarian cancer in a clinical trial since 
2013, and one of the practices (Tampa General) had referred three women with ovarian cancer 
to another facility for a clinical trial (see Table 4.2).  
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Table 4.2. Women with ovarian cancer enrolled in clinical trials at your site, or referred to 
another site, since 2013. 
 
About how many women with ovarian cancer 
were enrolled in clinical\trials at your site in 
2013? 
About how many women with ovarian cancer 
were referred to another\practice for a clinical 
trial in 2013? 
0 3 
26 Unknown 
0 Don’t know 
0 0 
0 0 
Unanswered Unanswered 
0 Unknown 
 
Nurses estimated the racial breakdown of their practices, averaged for all seven responses, to 
be 76% white, 15% black, 5% Asian, and 3% unknown (see Table 4.3A). The proportion of Non-
Hispanic to Hispanic ethnicity was, on average, 93% and 7% respectively (Table 4.3B).  
Table 4.3. Practice nurses’ estimated distribution of patients’ race and ethnicity. 
A. Estimated racial stratification of ovarian cancer patients. 
Answer Min Value Max Value Average Value 
Standard 
Deviation Responses 
White or 
Caucasian 13.00 100.00 76.14 31.37 7 
Black or 
African 
American 
0.00 75.00 14.57 26.98 7 
Asian or 
Pacific 
Islander 
0.00 20.00 4.71 7.63 7 
Other or 
unknown 0.00 10.00 3.14 3.72 7 
 
B. Estimated distribution of Hispanic or Non-Hispanic stratification of ovarian cancer 
patients. 
Answer Min Value Max Value Average Value 
Standard 
Deviation Responses 
Non-
Hispanic 
(any race) 
86.00 100.00 93.29 5.44 7 
Hispanic 
(any race) 0.00 14.00 6.86 5.52 7 
 
In response to the question as to whether ovarian cancer clinical trials are a priority at your own 
particular practice site, nearly three-quarters of the nurses said they are not (Table 4.4). 
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Table 4.4. Are clinical trials a priority at your practice site? 
Yes 2 29% 
No 5 71% 
Total 7 100% 
 
With regard to the outer setting, all practices said they have websites and are sometimes 
mentioned in the newspaper or on local television. All seven practice nurses reported having a 
collaborative relationship with another hospital for clinical trials; five named Moffitt Cancer 
Center, one named Florida Hospital and Moffitt Cancer Center, and one named Tampa General. 
Characteristics within the inner setting include provision of patient education materials, which all  
seven practice sites provide with regard to treatment and symptoms, but less than three-fourths 
provide for clinical trials and support groups (Table 4.5A).  
When asked if the practice provides patient education literature on clinical trials (Table 4.5B), 
however, the proportion of those that said yes exceeded the answer (71%) provided in the 
preceding table, which may have been interpreted as oral discourse, which, logically would 
make one expect a higher percentage in the previous rather than the subsequent table. 
Table 4.5. Practices that provide patient education. 
 
When asked if the practice has a plan for presenting the option of a clinical trial to women with 
ovarian cancer, 57% responded that there is no plan (Table 4.6A).  
 
 
A. Education focused on treatment, symptoms, clinical trials, and/or support groups. 
Treatment 7 100% 
Symptoms 7 100% 
Clinical trials 5 71% 
Support groups 5 71% 
B. Practices that provide patient education literature on clinical trials. 
Yes 6 86% 
No 1 14% 
Total 7 100% 
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If a woman with ovarian cancer initiates a question about clinical trials, most nurses said she is 
referred to the physician for further discussion (Table 4.6B). 
 
Table 4.6. Nurses were asked questions about practice policy related to clinical trials. 
	
Nurses were also asked who is most likely to bring up the subject of clinical trials and most said 
the physician (71%), followed by either the nurse practitioner or research nurse (each 14%), 
with no one selecting the primary care nurses or the patient as being likely to bring up the 
subject of a clinical trial (Table 4.7).  
Table 4.7. When clinical trials are discussed, who is most likely to bring up the topic? 
Physician 5 71% 
Nurse practitioner 1 14% 
Research nurse 1 14% 
Primary care nurse 0 0% 
Ovarian cancer patient 0 0% 
 
The team members that nurses felt should be able to discuss clinical trials with the patient are 
shown in Table 4.8; the physician was selected by all, then the nurse practitioner or research 
nurse, with the primary care nurses being the least selected option. 
 
  
A. Does the practice have a plan for presenting the option of a clinical trial to women 
with ovarian cancer? 
Yes 3 43% 
No 4 57% 
Total 7 100% 
B.  If a patient asks about clinical trials, is she referred to the doctor for further 
discussion? 
Yes 5 71% 
No 2 29% 
Total 7 100% 
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Table 4.8. Nurses were asked to specify which team member(s) they feel should be able to 
discuss clinical trials. (They were asked to select all that apply.) 
 
Physician 7 100% 
Nurse practitioner 6 86% 
Research nurse 6 86% 
Primary care nurse 5 71% 
  
Less than half of the practice nurses said they use clinical-trial matching websites; those that do 
use them were asked to specify which sites they use, shown in Table 4.9. 
Table 4.9. Nurses were asked if they ever use trial matching websites. 
Yes.  
If so, write the name(s) of the website(s) you find most helpful. 
3 43% 
• NCI.gov http://www.cancer.gov/  
• clinicaltrials.gov https://clinicaltrials.gov/  
• FloridaCancerTrials http://floridacancertrials.com/en/ 
• Moffitt Cancer Center 
https://moffitt.org/clinical-trials-
research/?utm_source=Socius&utm_medium=BingCPC&utm_campaign=Socius 
No 4 57% 
Total 7 100% 
 
Although less than a third of the nurses reported that clinical trials are a priority in their practice, 
more than half of the nurses responded that their practice does provide clinical-trial education to 
staff (Table 4.10). 
Table 4.10. Does your practice educate staff about clinical trials? 
Yes 4 57% 
No 3 43% 
Total 7 100% 
 
With regard to cost coverage of clinical trials, 86% of nurses reported that they believe health 
insurance would cover standard-of-care costs in a clinical trial, while only 14% (one nurse) 
believed that the Affordable Care Act would cover clinical trial costs (see Table 4.11 and 4.12). 
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Table 4.11. Clinical trials and insurance coverage. 
Do you believe that health insurance covers standard-of-care costs in a clinical trial? 
Yes 6 86% 
No 1 14% 
Total 7 100% 
 
Table 4.12. Would the Affordable Care Act (ACA) would be helpful or unhelpful in covering 
patients’ clinical trial costs? 
Helpful (please 
briefly explain why) 
May provide patients with better access to care 1 14% 
Unhelpful (please 
briefly explain why) 
I don’t know that it would cover clinical trials 6 86% 
Will limit what we can offer as SOC. 
Standard of care is all that is typically covered 
Many of the plans available have narrow networks thus not 
providing coverage for clinical trials 
 
Nurses were asked about the timing of informing ovarian cancer patients about clinical trials 
related to the time when they are diagnosed, and they were also asked if they thought clinical 
trials should be the last resort after all standards of care have failed (see Tables 4.13). While 
nearly three-quarters of the nurses thought patients should be informed about clinical trials right 
after being diagnosed with ovarian cancer, 43% of the nurses felt clinical trials should be the last 
resort after all known treatment have failed. 
Table 4.13. Timing the discussion of clinical trials 
A. Should ovarian cancer patients be informed about clinical trials right after being 
diagnosed? 
Yes 5 71% 
No 2 29% 
Total 7 100% 
 
More than half of the nurses stated that women with ovarian cancer sometimes ask about 
clinical trials (Table 4.14), which conforms to their response in Table 4.7 that patients are least 
likely to initiate discussion of trials; after a physician initiates trial discussion, the patient may 
B. Should clinical trials be the last resort after all known treatments have failed? 
Yes 3 43% 
No 4 57% 
Total 7 100% 
57	
	
share thoughts or questions with the nurse, who usually spends more time talking to and 
educating patients. 
Table 4.14. Do women with ovarian cancer ever ask you about clinical trials? 
Yes 4 57% 
No 3 43% 
Total 7 100% 
 
Nurses provided the following reasons women have given for not wanting to participate in an 
ovarian cancer clinical trial: 
• Do not want treatment anymore (usually have been through multiple regimens) 
• Time involved for visits and treatment 
• Want to try interventions that are standard of care first 
• Afraid of the unknown 
• They want up-front therapy 
• Concern about lack of response 
Most nurses (71%) said they are comfortable answering patients’ questions about clinical trials, 
feel well-informed when patients ask about clinical trials, and have practice resources to help 
them answer questions (Table 4.15). 
Table 4.15. Questions asked nurses about feeling comfortable, well-informed, and having 
accessible to resources when asked about clinical trials. 
A. Are you comfortable answering patients’ questions about clinical trials? 
Yes 5 71% 
No 2 29% 
Total 7 100% 
B. Do you feel well-informed when patients ask about clinical trials? 
Yes 5 71% 
No 2 29% 
Total 7 100% 
Table 4.15 continues on next page.  
58	
	
Table 4.15 (continued)	
C. Does your practice have resources to help you answer questions about clinical 
trials? 
Yes 5 71% 
No 2 29% 
Total 7 100% 
 
The practice resources that nurses listed include the telephone number for the clinical trial 
nurse, being well-informed through training as a research nurse, having literature, and using 
internet resources. Only 29% of nurses said that their practice team discusses ovarian cancer 
clinical trials during team meetings (Table 4.16A). 
Table 4.16. Practice information, desire for more knowledge, and practice team plans. 
A. Does your practice discuss ovarian cancer clinical trials during team meetings? 
Yes 2 29% 
No 5 71% 
Total 7 100% 
B. Would you like to know more about clinical trials? 
Yes 4 57% 
No 3 43% 
Total 7 100% 
C. Does your team have a plan for offering clinical trials to women with recurrent or 
persistent ovarian cancer? 
Yes 4 57% 
No 3 43% 
Total 7 100% 
D. If you do not have a clinical trial for a woman with ovarian cancer who wants one, do 
you have a plan to help her find one? 
Yes 5 71% 
No 2 29% 
Total 7 100% 
  
Nurses were asked if they would like to know more about clinical trials, and more than 
half said yes, while less than half said no (Table 4.16B). Asked if the practice has a plan for 
offering clinical trials to women with recurrent or persistent ovarian cancer, more than half of the 
nurses said yes, while less than half said no (Table 4.16C). Those who said yes were asked to 
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elaborate on the plan, which included a referral to Moffitt, use of a clinical trial priority tree and 
list of trials, and one who thought so but was uncertain of what the plan was. 
While four of seven nurses said their team has a plan for offering clinical trials to women 
with recurrent or persistent ovarian cancer (Table 4.16C), five nurses said that if they do not 
have an on-site trial for a woman who desires a study, they have a plan to help her find one 
(Table 4.16D). The five nurses who have a plan cited their plans as calling to set up an 
appointment for the patient, searching for a trial themselves, referring to Moffitt or to a tertiary 
center. 
 
Nurses were asked to share final thoughts, which follow: 
• I have confidence in the trials at Moffitt and the patients that we have referred are always 
pleased with the options and care 
• Need to have increased community awareness that trials are available; local oncologists 
should refer sooner. 
• It would be great to have more information available to patient about clinical research. 
• We have a working relationship with Moffitt. 
 
Women with Ovarian Cancer 
 
As shown in Table 4.17, participants with ovarian cancer ranged in age from 28 to 79, with a 
mean age of 64.1 (SD 12.29) and were 90% white and 10% black. Fourteen women (70%) were 
married, three (15%) were divorced or separated, two (10%) were widowed, and one (5%) was 
single. Twelve women (60%) reported that they were retired, three (15%) stated they were 
unemployed, two (10%) said they work part time, and three (15%) stated they work full time. 
Three women (15%) had stage IV disease, fourteen (70%) were stage III, one (5%) was stage 
II, and two (10%) were stage I.  
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Table 4.17. Age, Race, marital and employment status, and stage of disease of participants 
with ovarian cancer (N=20). 
Age When Completing Survey 
Range Mean Std Dev Median 
28-79 64.1 12.29 67 
  
Race 
White Black 
18 2 
90% 10% 
 
Marital Status 
Married Divorced or separated Widowed Single 
14 3 2 1 
70% 15% 10% 5% 
 
Employment Status 
Employed Full time Employed Part time Retired Unemployed 
3 2 12 3 
15% 10% 60% 15% 
 
Stages of Disease 
I II III IV 
2 1 14 3 
10% 5% 70% 15% 
    
 
Participants were asked the following questions with regard to clinical trials: 
1. Have you ever been in a clinical trial? 
2. Would you consider a clinical trial if asked? 
3. Have you ever been offered a trial but failed to meet the inclusion criteria?  
4. Does your doctor have clinical trials? 
5. Has your doctor or nurse ever discussed clinical trials with you? 
6. Have you ever asked your doctor or nurse about clinical trials? 
Nearly half of the participants (see Table 4.18) have never been in a clinical trial, yet 90% of the 
women said they would consider a clinical trial if offered in the future; the two who would not  
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Table 4.18. Women with ovarian cancer, past participation in clinical trials, intention to 
participate in the future, and interaction with their physician (N=20). 
Questions Yes % of 
total 
No % of 
total 
Have you ever been in a clinical trial? 9 45% 11 55% 
If you were offered a clinical trial in the near future, 
would you\consider it? 
18 90% 2 10% 
Have you ever been offered a clinical trial then failed to 
meet the\inclusion criteria? 
4 20% 16 80% 
Does your doctor offer clinical trials? 9 45% 11 55% 
Has your doctor or nurse ever discussed clinical trials 
with you? 
13 65% 7 35% 
Have you ever asked your doctor or nurse about clinical 
trials? 
13 65% 7 35% 
 
consider a clinical trial stated their reasons, which follow: 
• I am a 12 year survivor and would most probably do traditional chemo, but would be 
open to hearing my options. 
•  
• At present time I am maintaining within normal range CA125 with alternative Ave'Ultra & 
IMMPOWER capsules. 
 
Four participants who wanted to participate in a clinical trial were unable to enroll because they 
failed to meet the inclusion criteria; the following reasons for failing were provided by two of the 
women: 
• My tissue from surgery didn't match what they needed. 
• —past resolved health issue unrelated to current illness but may be induced by trial 
medication. 
Thirteen women (65%) said their doctor or nurse had discussed clinical trials, while seven 
women (35%) said provider discussion had never occurred. Thirteen women (65%, not the 
same individuals) said they have asked their doctor or nurse about clinical trials, and seven 
women (35%) have not (see Table 4.18). 
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Women were asked if they think it makes sense to consider a clinical trial right after 
being diagnosed with cancer, and more than half of the women said yes (see Table 4.19). 
Those who said “no” were stages III and IV, while those who said “yes” included two women 
with stage I disease and one woman with stage II disease, along with eight women who are 
stage III and one who is stage IV.  
Table 4.19. Does it make sense to consider a clinical trial right after being diagnosed with 
ovarian cancer? (N=20). 
All Stages Combined Stage I Stage II Stage III Stage IV 
Yes 12 60% 2 (17% of 
“Yes”) 
1 (<1% of 
“Yes”) 
8 (67% of 
“Yes” 
1 (<1% of 
“Yes”) 
No 8 40% 0 0 6 (75% of 
“No”) 
2 (25% of 
“No”) 
	
Reasons given by the women who said clinical trials should not be considered right after being 
diagnosed follow. 
• Cutting edge treatment (stage III) 
• Because hopefully the standard treatment will work for you. I won't consider clinical trials 
unless standard treatment didn't work right away. (stage III) 
• Try standard treatment first (stage III) 
• Would want to try standard care treatment first (stage III) 
• They used stronger chem[otherapy;]  clinical trial was not brought up. (stage III) 
• You need to do as your oncologist suggests so you know you are getting treatment and 
in clinical trials you don't know. (stage III) 
• Should start off with standard of care. (stage IV) 
• Too much information all at once. Need some time to handle diagnosis before making 
decisions. Need time to investigate standard protocols before looking into trials. (stage 
IV) 
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Most of the women said that it does make sense to consider clinical trials early upon being 
diagnosed, and eleven of the twelve women provided their rationale, which follows. 
• Only the "gold standard" of treatment was prescribed and then changed to a stronger 
chemotherapy due to my cell type. Options were not discussed. (stage I) 
• Many women do not realize that clinical trials should not just be considered at end of 
treatment, but at diagnosis. (stage I) 
• I would like to stay proactive (stage III) 
• Cutting edge treatment (stage III) 
• To help beat cancer. (stage III) 
• I would say yes if I had no other options, but so far I have had other options. (stage III) 
• Keep all options open (stage III) 
• To save another. (stage III) 
• If it will address the cancer appropriately. (stage III) 
• Some treatment interfere with clinical trials (stage III) 
• You may very likely be given a very new promising drug that could greatly impact your 
survival. (stage IV) 
 
Women were asked if they felt their health insurance covers standard-of-care costs in a clinical 
trial, and whether they thought the Affordable Care Act would be helpful in contributing to clinical 
trial participation (Table 4.20). 
Table 4.20. Women’s perceptions about clinical trial cost coverage by health insurance and the 
Affordable Care Act. 
Do you believe that health insurance covers 
standard-of-care costs in a clinical trial? (Q35) 86% Yes  14% No 
Do you think the ACA will be helpful in covering 
CT costs? (Q36) 14% Yes  86% No 
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QCA Analysis 
The outcome of interest was enrollment in clinical trials by women with ovarian cancer. The 
influents of enrollment were sought for two populations: women with ovarian cancer and nurses 
in medical or gynecologic oncology practices. The influents were considered within the domains 
of the Consolidated Framework for Implementation Research (CFIR), introduced and explained 
in earlier chapters.   
Consistency for crisp sets is the percentage of cases in each row displaying the 
outcome. Consistency scores of either 1 or 0 indicate perfect consistency for a given row, while 
a score of 0.50 indicates perfect inconsistency. When evaluating possible necessary conditions, 
rows with consistency of ≥ 75% should be coded 1 for the presence of the outcome variable, 
while those below 75% should be coded 0 for absence of the outcome variable (personal 
communication with Dr. Charles Ragin on September 14, 2015). "Coverage" is the percentage 
out of all observations that exhibit that implication or inference, and "consistency" is the 
percentage of observations conforming to that combination of variables having that particular 
value of the dependent variable or outcome, which are calculated and reported.  
Patients 
QCA analysis is an iterative process with multiple variables that may contribute to the 
cause of an outcome. If too many conditions are used, it may be more difficult to drill down to 
the key factors, thus if there are similar conditions, those that are related can be consolidated 
into one. For example, instead of including a separate condition for each team member within 
the clinical practice (e.g., physician, nurse, nurse practitioner), it can be advantageous to 
combine each team member into one condition that means any practice team member 
discussed the issue.  Table 4.21 is a matrix for the outcome of enrolling in a clinical trial. In the 
table, in the second column, there is a 1 for presence of the condition and a 0 for absence of the 
condition. The labels A to F, at top right in the table, are explained in the last row. Each 
represents a condition felt to be a cause of enrollment in a clinical trial. 
65	
	
Table 4.21. Data matrix of conditions considered for inclusion in QCA. 
Set membership Outcome (1 means 
participation is 
present; 0 means 
participation is absent) 
Conditions (1 = Present and 0 = Absent) 
A B C D E F 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 0 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was in a CT 1 1 1 1 1 1 1 
Was not in a CT 0 1 0 0 0 1 1 
Was not in a CT 0 1 1 0 0 1 1 
Was not in a CT 0 1 1 0 0 1 1 
Was not in a CT 0 1 0 1 1 0 1 
Was not in a CT 0 1 1 0 1 1 1 
Was not in a CT 0 1 0 0 0 1 1 
Was not in a CT 0 1 1 0 0 0 1 
Was not in a CT 0 1 1 1 1 1 1 
Was not in a CT 0 1 1 0 0 1 1 
Was not in a CT 0 1 1 1 1 1 1 
Was not in a CT 0 1 1 1 1 1 1 
A =  CT available             B =  Stage III/IV            C =  We discuss 
D =  Any suggest             E =  Want information   F =  Family supports 
 
Women with Ovarian Cancer 
Table 4.22 is a truth table for the hypothesized potential conditional configurations. In the next-
to-last column is the number of cases that were included in each configuration. Raw consistency 
is the percentage of the number of cases that were actually in the configuration of conditions. 
The revised truth table contains less conditions in the hope of deriving a higher consistency 
score before running the analysis. Cases in Table 4.23 with consistency below 75% were coded 
0, while cases with consistency of at least 75% were coded 1. Remainder rows, which have no 
cases in them, were deleted. 
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Table 4.22. Truth Table of Hypothesized Potential Conditional Configurations 
Row CT 
available 
st3or4 wediscuss anysugg wantinfo famsupp Number of 
cases in 
configuration 
Raw 
consistency 
i. 1 1 1 1 1 1 11 0.818182 
ii. 1 1 0 0 1 1 3 0.000000 
iii. 1 0 0 0 1 1 2 0.000000 
iv. 1 1 1 0 1 1 1 1.000000 
v. 1 1 0 1 1 1 1 0.000000 
vi. 1 1 0 0 0 1 1 0.000000 
vii. 1 0 1 1 0 1 1 0.000000 
 
Table 4.23. Revised Truth Table. 
Row Stage 3 or 4 wediscuss Wantinfo Number of 
cases in 
configuration 
Raw 
consistency 
i. 1 1 1 12 0.833333 
ii. 1 0 1 4 0.000000 
iii. 0 0 1 2 0.000000 
iv. 1 0 0 1 0.000000 
v. 1 1 0 1 0.000000 
 
Table 4.24 shows the QCA solutions and consistency and coverage for women enrolled (and 
not enrolled) in clinical trials.  Coverage is the portion out of all observations that reflect the 
inference. Consistency is the portion of observations that conform to that combination of 
variables having that particular value of the dependent variable. The desire to achieve perfect 
coverage and consistency values of 1, if possible, required another combination of variables, 
shown in the following truth table (see 4.25). Because acceptance of consistency below .80 is 
not recommended, this combination of conditions was not pursued. The best result with the  
highest consistency and coverage scores is the condition cluster in tables 4.23 and 4.24. 
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Table 4.24. QCA Solutions, Consistency and Coverage for women enrolled in clinical trials and 
women not enrolled in clinical trials. 
Outcome  Solutions Consistency Raw 
Coverage 
Unique 
Coverage 
Enrolled 
in CTs 
Complex (solution 
coverage:1;solution 
consistency: 
0.83333) 
st3or4*wediscuss*wantinfo 0.83333 1.0 1.0 
Parsimonious 
(solution 
coverage:1;solution 
consistency: 
0.83333) 
st3or4*wediscuss 
 
*wantinfo 
0.83333 1.0 0.0 
Intermediate 
(solution 
coverage:1;solution 
consistency: 
0.83333) 
wantinfo*wediscuss*st3or4 0.83333 1.0 1.0 
NOT 
Enrolled 
in CTs 
Complex 
(solution coverage: 
0.8 and solution 
consistency:1.0) 
st3or4*~wediscuss 
~wediscuss*wantinfo 
~st3or4*wediscuss*~wantinfo 
1.0 
1.0 
1.0 
0.5 
0.6 
0.1 
0.1 
0.2 
0.1 
Parsimonious 
(solution coverage: 
0.8 and solution 
consistency:1.0) 
~wediscuss 
~wantinfo 
~st3or4 
1.0 
1.0 
1.0 
0.7 
0.2 
0.3 
0.4 
0.0 
0.0 
Intermediate 
(solution coverage: 
0.8 and solution 
consistency:1.0) 
wantinfo* ~wediscuss 
~wediscuss*st3or4 
~wantinfo*wediscuss*~st3or4 
1.0 
1.0 
1.0 
0.6 
0.5 
0.1 
0.2 
0.1 
0.1 
 
 
Table 4.25. Truth Table Combination with Consistency Score Below 0.80 
Row anysug
gdisc 
st3or4 wantinfo famsupp Number of cases in 
configuration 
Raw 
consistency 
i. 1 1 1 1 13 0.769231 
ii. 0 1 1 1 3 0.000000 
iii. 0 0 1 1 2 0.000000 
iv. 1 0 0 1 1 0.000000 
 
An attempt was made to introduce another variable associated with women who did not 
participate in clinical trials and the possible influence of preference for standard of care. Of 
eleven women who were not in a clinical trial, only five clarified their preference for the standard 
of care, thus consideration of that variable did not produce a viable solution.  
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Setting the dependent variable as clinical trial enrollment with several combinations of 
variables yielded no considerable consistency or coverage for a crisp set analysis. A necessity 
analysis, which does not produce a truth table, was conducted using nonparticipation in a trial 
and preference for standard of care and presence or absence of provider discussion (see Table 
4.26). A perfect solution was not reached because interviews would be necessary to determine 
preference for standard of care by all eleven of the nonparticipants. The analysis below is 
saying that there is a correlation between not participating and preferring the standard of care 
while having no provider discussion, and that the opposite is true for participants. Again, it is not 
a perfect solution because interviews would be needed to clarify missing information for the 
conditions tested. 
Table 4.26. Necessity Analysis for Trial Participation Considering Preference for Standard of 
Care and Provider Discussion 
Outcome variable Conditions Tested Consistency Coverage 
~partct prefers soc+~provdisc 0.727273 1.000000 
  partct ~prefers soc+provdisc 1.000000 0.600000 
 
 
Practice Nurses 
Only seven nurses responded to the survey, making the use of QCA challenging. Nevertheless, 
it was interesting to explore nurses’ feelings about which practice team members should be able 
to discuss clinical trials with patients. We see a raw consistency of 1 in all combinations 
because everyone in each combination is represented. There is nothing notable in this 
information because the sample is very small and all of the nurses were closely affiliated with 
tertiary care centers. 
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Table 4.27. Truth Table for Nurses regarding practice team members who should be 
communicating information on clinical trials. 
Row Physician Nurse 
practitioner 
Primary 
nurse 
Research 
nurse 
Number of 
cases in 
configuration 
Raw 
consistency 
i. 1 1 1 1 5 1.0 
ii. 1 1 0 1 1 1.0 
iii. 1 0 0 0 1 1.0 
 
In the following truth table (Table 4.28), the intent was to see if those who have a plan for 
offering clinical trials to women with ovarian cancer feel informed and are comfortable with 
requests for information.  
Table 4.28. Truth Table for nurses in practices that have a plan to help find trials, and its impact 
on feeling informed and being comfortable with questions. 
Row comfquest feelinformed Number of cases in 
configuration 
Raw consistency 
i. 1 1 5 0.8 
ii. 0 0 2 0.5 
 
The intermediate solution for this condition set follows. The small sample size prevents one from 
drawing conclusions, but most of the observations for this pattern within the small sample felt 
informed and were comfortable answering patients’ questions when the practice team had a 
definitive plan. 
Table 4.29. Truth Table Analysis for the impact of having a plan on feeling informed and being 
comfortable with questions. 
feelinformed*comfquest coverage consistency 
0.800000 0.800000 
 
Few causality patterns could be found within the nursing group because of the small sample 
size and wide variation within that small group. 
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Results by Study Population for the Research Questions 
This exploratory multiple case study looked at factors within the domains of the 
Consolidated Framework for Implementation Research (CFIR) associated within enrollment in 
clinical trials. The factors were based on data from two populations: women with ovarian cancer, 
and nurses in gynecologic and medical oncology practices. There is no existing definitive 
process across cancer centers and oncology practices, some of which do not offer any ovarian 
cancer clinical trials. A definitive process between/among institutions does not exist, thus 
making the search for sufficient conditions associated with enrollment in clinical trials 
challenging. The focus thus was on necessary conditions. The research questions follow: 
1. What necessary and/or sufficient factors, based on Qualitative Comparative 
Analysis (QCA)(Ragin, 1989), within the gynecologic oncology practice network 
in Florida, enable a woman with recurrent or persistent ovarian cancer to enroll in 
a clinical trial? 
2. What barriers and facilitators exist with regard to enrolling women with ovarian 
cancer in clinical trials? 
Women with Ovarian Cancer 
Research Question 1. Despite multiple attempts to try numerous iterative factor 
combinations, the investigator was unable to achieve a perfect solution of 1.0 for coverage and 
1.0 for consistency. The highest consistency (1.0) and coverage (0.83) for women who have 
been in clinical trials was that they were stage III/IV, wanted information, and engaged in 
discussion about clinical trials, making those factors necessary for enrollment in a study. The 
reason that consistency may not have achieved 1.0 is that one of the patients had participated 
in arthritis clinical trials and may not have participated in an ovarian cancer treatment study, and 
she was not able to be reached by telephone for clarification. Another unique condition existed 
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with a woman who said neither her nurse nor physician had suggested a trial, but she had 
participated in one; she thus may have proactively sought one on her own.   
With regard to intentions or willingness to consider a clinical trial, some women said they 
would not participate because they were currently in treatment, thus it was unclear whether they 
would pursue a clinical trial if they were not in treatment or were in treatment that failed to 
stabilize or diminish their cancer. 
Early stage patients who were cured of ovarian cancer were amenable to considering 
clinical trials, but no conclusion can be drawn for that very small subset of three early stage (I/II) 
patients who consented to this study. Women with early and later stage ovarian cancer, 
however, all stated a desire for information on clinical trials, and all believe their family members 
would support them if they participated in a clinical trial.  Women indicated that they hear about 
and discuss clinical trials mostly with their physician; for many physicians, however, including 
some who are affiliated with institutions that offer clinical trials, clinical studies are not a priority. 
Women are not always aware that recurrent cancer is terminal, or that the “gold standard” is not 
synonymous with a cure.  
Research Question 2. What barriers and facilitators, practitioner and patient-specific, 
exist with regard to enrolling women with ovarian cancer in clinical trials? 
Facilitators are contributors to being in a clinical trial, expressed by at least 50% of those 
who have been in a clinical trial. Barriers impede participation; in Table 4.30, below, the scores 
with the greatest discrepancies between those who have been in a clinical trial and those who 
have not, suggest obstacles to being in a clinical trial.  
The data thus suggests that discussion with the provider of care, to some extent the 
existence of patient-accessible clinical trial literature in the practice, knowledge that health 
insurance covers standard of care costs, and the provider offering clinical trials are facilitators 
for participation. Absence of those factors thus constitutes a barrier. 
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Table 4.30. Factors for women who have and have not been in clinical trials, suggesting facilitators 
and barriers, are compared. A facilitator is a factor that is true for at least half of the women who 
participated in clinical trials. A barrier is a factor for which there is a difference of at least 20 
percentage points. Widely discrepant scores suggest that awareness that facilitated participation for 
some women, when misperceived, is a barrier to participation for other women. Also included, for 
interest in the population of women who have not been in a clinical trial, is the question on intention 
(third column from left) to be in a clinical trial and its relationship to intention to use a trial matching 
tool, should one exist (fourth column from right). 
Participa-
ted in at 
least 1 CT  
Your 
provider 
has dis-
cussed 
CTs with 
you 
(1yes, 
0no) 
If offered 
a CT, you 
would 
consider 
it (1yes, 
0no) 
You have 
seen patient 
education 
literature on 
CTs in your 
provider's 
office. 
(1yes, 0no) 
It makes 
sense to 
consider a 
CT soon 
after you are 
diagnosed. 
(1yes, 0no) 
You do 
not 
believe 
CTs are 
an option 
only after 
SOC 
fails. 
(1yes, 
0no) 
If your 
oncologist 
had a 
website 
trial-
matching 
tool, you 
would use it. 
(1yes, 0no) 
Health 
insurance 
would cover 
the 
standard of 
care costs 
involved in 
a CT. (1yes, 
0no) 
The ACA 
would be 
helpful in 
support-
ing CT 
costs. 
(1yes, 
0no) 
Your   
provider  
offers 
CTs 
 
9 9 8 6 5 6 7 8 5 7 
100% 100% 89% 67% 56% 67% 78% 89% 56% 78% 
Did not 
participate 
in a CT 
Your 
provider 
has dis-
cussed 
CTs with 
you 
(1yes, 
0no) 
If offered 
a CT, you 
would 
consider 
it (1yes, 
0no) 
You have 
seen patient 
education 
literature on 
CTs in your 
provider's 
office. 
(1yes, 0no) 
It makes 
sense to 
consider a 
CT soon 
after you are 
diagnosed. 
(1yes, 0no) 
You do 
not 
believe 
CTs are 
an option 
only after 
SOC 
fails. 
(1yes, 
0no) 
If your 
oncologist 
had a 
website 
trial-
matching 
tool, you 
would use it. 
(1yes, 0no) 
Health 
insurance 
would cover 
the 
standard of 
care costs 
involved in 
a CT. (1yes, 
0no) 
The ACA 
would be 
helpful in 
support-
ing CT 
costs. 
(1yes, 
0no) 
Your   
provider  
offers 
CTs 
 
11 4 10 3 7 7 10 6 6 2 
100% 36% 91% 27% 64% 64% 91% 55% 55% 18% 
 
 
Practice Nurses  
Research Question 1. As previously explained, the small sample of nurses (7) was not 
conducive to yielding a combination of conditions with coverage and consistency of 1.0. The 
highest coverage and consistency were 0.8, for the impact of having a practice team plan 
related to enrolling women with ovarian cancer in clinical trials, resulting in nurses feeling 
informed and comfortable with questions women might ask about trials. Numerous combinations 
of conditions were tried, and nothing else resulted in coverage and consistency that exceeded 
0.75. 
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Research Question 2. What barriers and facilitators, practitioner and patient 
specific, exist with regard to enrolling women with ovarian cancer in clinical trials? 
More clinical-trial enrolling-referring nurses have a practice team plan (67% versus 25%, in 
Table 4.31 below), suggesting that having a plan is a facilitator and not having one is a barrier.  
 
Table 4.31. Factors for nurses who have and have not enrolled or referred at least one woman 
to a facility for enrollment in a clinical trial are compared. A facilitator is a factor that is true for 
≥50% of practice nurses. A barrier is a factor for which there is a difference of ≥ 20%. 
Enrolled 
or 
referred 
at least 1 
woman 
for a CT 
OvCa 
CTs are 
a 
practice 
priority 
(1yes, 
0no) 
Your 
practice 
or clinic 
educate
s staff 
on CTs 
(1yes, 
0no) 
 
You feel 
well 
informed 
and 
comfortabl
e when a 
patient 
asks about 
clinical 
trials. 
(1yes, 0no) 
Your 
practice 
has a plan 
for 
presentin
g the CT 
option to 
women 
with ovca 
(1yes, 
0no) 
You 
believe 
health 
insuranc
e covers 
standard 
of care 
costs for 
CTs? 
(1yes, 
0no) 
You 
believe 
the ACA 
will be 
helpful (1) 
or 
unhelpful 
(0) in 
supportin
g CT 
costs. 
CTs 
should 
be the 
last 
resort 
after 
SOC 
Tx 
fails 
(1yes, 
0no) 
Women 
with ovca 
should be 
informed 
about 
CTs as 
soon as 
possible 
after 
being 
diagnose
d (1yes, 
0no) 
Women 
with ovca 
sometime
s ask you 
about 
CTs. 
1 0 1 1 0 1 0 1 1 1 
1 1 0 1 1 1 0 0 1 1 
1 0 1 0 1 1 1 0 1 1 
3 1 2 2 2 3 1 1 3 3 
  33% 67% 67% 67% 100% 33% 33% 100% 100% 
 Did not 
enroll or 
refer any 
women 
for a CT 
OvCa 
CTs are 
a 
practice 
priority 
(1yes, 
0no) 
Your 
practice 
or clinic 
educates 
staff on 
CTs 
(1yes, 
0no) 
You feel 
well 
informed 
and 
comfortable 
when a 
patient asks 
about 
clinical 
trials. (1yes, 
0no) 
Your 
practice 
has a plan 
for 
presentin
g the CT 
option to 
women 
with ovca 
(1yes, 
0no) 
You 
believe 
health 
insuranc
e covers 
standard 
of care 
costs for 
CTs? 
(1yes, 
0no) 
You 
believe 
the ACA 
will be 
helpful (1) 
or 
unhelpful 
(0) in 
supportin
g CT 
costs. 
CTs 
shoul
d be 
the 
last 
resort 
after 
SOC 
Tx 
fails 
(1yes, 
0no) 
Women 
with ovca 
should be 
informed 
about 
CTs as 
soon as 
possible 
after 
being 
diagnose
d (1yes, 
0no) 
Women 
with ovca 
sometime
s ask you 
about 
CTs. 
0 0 0 1 0 1 0 1 0 1 
0 0 0 0 0 1 0 0 0 0 
0 0 1 1 0 1 0 1 1 0 
0 1 1 1 1 0 0 0 1 0 
4 1 2 3 1 3 0 2 2 1 
0% 25% 50% 75% 25% 75% 0% 50% 50% 25% 
74	
	
Additional facilitators are recognition that health insurance covers standard of care costs, 
and that the ACA supports clinical trial costs. While not quite reaching a 20% difference, the 
perception that clinical trials should be the last resort after the standard of care has failed is 
likely impeding eligibility because of limits on maximum prior regimens as well as having poor 
ECOG scores associated with complications of advanced disease. The belief that women 
should be informed about clinical trials as early as possible after diagnosis is a facilitator; 
absence of that belief is thus a barrier to enrollment. The fact that women bring up the 
discussion about clinical trials to enrollers may be related to the population that seeks care at 
facilities that offer clinical trials; regardless, it suggests that women would do well to ask the 
question, which, if no trials are offered on site, may result in a referral. Table 4.18 suggests that 
practice resources could be used to improve knowledge and comfort levels among all nurses. .  
Relating Results to the Theoretical Model 
A review of survey results identified opportunities for improvement in the outer and inner 
settings, and with regard to individuals and the overall process. The conditions and scores that 
represent opportunities for improvement are shown in bold font in the following tables for 
practices (Table 4.32) and for women with ovarian cancer (Table 4.33). The tables are followed 
by composite illustrations of the items that can be improved within each level of the 
Consolidated Framework for Implementation Research (CFIR) framework. Figure 4.1 
juxtaposes practice findings within the CFIR levels; descriptive statistical findings are red, while 
QCA findings are purple. Figure 4.2 illustrates CFIR in which the findings of women with ovarian 
cancer have been inserted, teal indicating descriptive statistics, and purple indicating QCA 
findings. The results in the tables and figures are discussed in chapter five. 
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Table 4.32. Practice Scores for Descriptive Statistics that Indicate Opportunities for 
Improvement within the Theoretical Framework. 
Outer Setting:  Public and Professional Resources 
• Does your practice 
have a website? (Q22) 
100% have a website. 
• Does your practice 
have clinical trial 
resources for 
patients?   (Q47) 
71% Yes; 29% No and 0 computers for patients 
• Does your practice 
provide patient 
education literature on 
clinical trials? (Q31) 
86% Yes; 14% No 
• Does your practice 
educate staff about 
clinical trials? (Q34) 
57% Yes; 43% No  
 
• Does your practice 
have resources to help 
you answer questions 
about clinical trials? 
(Q43) 
71% Yes 
Inner Setting 
Networks/Communication 
When ovarian cancer clinical trials are discussed with patients, who is most likely to bring up the 
topic? (Q28) 
• The physician 5 
• Research nurse  1 
• Nurse practitioner  1 
• The patient 0 
• Primary care nurse 0 
Does your practice provide ovarian cancer patient education on any of the following? (Q23) 
• Treatment 7 
• Symptoms 7 
• Clinical trials 5 
Which of the following should be able to talk about ovarian cancer clinical trials with patients? 
(Q29) 
• Physicians 7 
• Nurse practitioners 6 
• Research nurses  6 
• Primary care nurses 5 
Do you ever use clinical trial websites? (Q32) 43% Yes    57% No 
Does your team discuss ovarian cancer clinical trials during team 
meetings? (Q46) 
29% Yes    71% No 
Table 4.32 continues on next page.	
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Table 4.32 (continued)	
When ovarian cancer clinical trials are discussed with patients, who is most likely to bring up the 
topic? (Q28) 
• The physician 5 
• Research nurse  1 
• Nurse practitioner  1 
• The patient 0 
• Primary care nurse 0 
Does your practice provide ovarian cancer patient education on any of the following? (Q23) 
• Treatment 7 
• Symptoms 7 
• Clinical trials 5 
• Support groups 5 
Which of the following should be able to talk about ovarian cancer clinical trials with 
patients? (Q29) 
• Physicians 7 
• Nurse practitioner 6 
• Research nurses 6 
• Primary care nurses 5 
Do you ever use clinical trial websites? (Q32) 43% Yes   57% No 
Does your team discuss ovarian cancer clinical trials during team 
meetings? (Q46) 
29% Yes   71% No 
If a patient asks about clinical trials, is she referred to the doctor for 
further discussion? (Q48) 
71% Yes   29% No 
 
Implementation and Learning Climate 
Do you think ovarian cancer clinical trials are a priority at your 
facility? (Q30) 
29% Yes  71% No 
Do you have computers in the waiting area for patients’ use? (Q33) 0% Yes   100% No 
Do you ever use clinical trial websites? (Q32) 43% Yes   57% No 
Does your practice provide patient education literature on clinical 
trials?  (Q31) 
86% Yes  14% No 
Does your practice educate staff about clinical trials? (Q34) 57% Yes  43% No 
Does your practice have resources to help you answer questions 
about clinical trials? (Q43) 
71% Yes  29% No 
Do you think ovarian cancer clinical trials are a priority at your 
facility? (Q30) 
29% Yes  71% No 
Do you have computers in the waiting area for patients’ use? (Q33) 0% Yes   100% No 
Do you ever use clinical trial websites? (Q32) 43% Yes   57% No 
Does your practice provide patient education literature on clinical 
trials?  (Q31) 
86% Yes  14% No 
Does your practice educate staff about clinical trials? (Q34) 57% Yes  43% No 
Does your practice have resources to help you answer questions 
about clinical trials? (Q43) 
71% Yes  29% No 
Table 4.32 continues on next page. 
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Table 4.32 (continued)	
Individual Level 
Do you believe that health insurance covers standard-of-care costs 
in a clinical trial? (Q35) 
86% Yes  14% No 
Do you think the ACA will be helpful in covering CT costs? (Q36) 14% Yes  86% No 
Do you want to know more about clinical trials? (Q44) 57% Yes  43% No 
Should ovarian cancer patients be informed about clinical trials as 
early as possible after being diagnosed? (Q37) 
71% Yes 29% No 
Should clinical trials be the last resort after all known treatments 
fail? (Q38) 
43% Yes 57% No 
Are you comfortable answering patients’ questions about clinical 
trials? (Q41) 
71% Yes 29% No 
Do you feel well informed when patients ask about clinical trials? 
(Q42) 
71% Yes 29% No 
Process Planning, Engaging, Executing 
Does your team have a plan for offering clinical trials to women with 
recurrent or persistent ovarian cancer? (Q45) 
57% Yes 43% No 
If you don’t have a clinical trial for a woman with ovarian cancer who 
wants one, do you have a plan to help her find one? (Q49) 
71% Yes  29% No 
 
 
Legend:  Red = descriptive statistics  Purple = QCA results 
 
Figure 4.1. Translating Practice Findings to Opportunities within the Consolidated Framework 
for Implementation Research (CFIR)   
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Table 4.33. Patients’ Scores for Descriptive Statistics that Indicate Opportunities for 
Improvement within the Theoretical Framework. 
Inner Setting 
Structural Characteristics for Women with Ovarian Cancer Yes % No % 
Has your doctor or nurse ever discussed clinical trials with you? 
(Q8) 13 65% 7 35% 
Does your oncologist offer clinical trials? (Q14) 9 45% 11 55% 
Networks/Communication Culture     
Which of the following providers of care have ever suggested you think about a clinical trial? 
Check all that apply (Q13) 
c Oncologist 12 
c Family member 5 
c Friend 5 
c Nurse practitioner 3 
c Research nurse 0 
c Primary care nurse 1 
Do you think website information for any of the following topics is helpful? Check all that apply 
(Q28) 
c Treatment 19 
c Clinical trials 19 
c Symptoms 18 
c Support groups 15 
 Yes % No % 
If you wanted a clinical trial that your practice didn’t offer, do you 
think your doctor would help you find a facility that offers the 
trial? (Q22) 
18 90% 2 10% 
Implementation, Incentives, Learning Climate Yes % No % 
Have you ever seen patient education literature on clinical trials 
in your doctor’s office? (Q17) 9 45% 11 55% 
Does your oncologist have a website? (Q26) 14 70% 6 30% 
If your oncologist had a website that helped you find matching 
clinical trials, would you use it? (Q27) 17 85% 3 15% 
Individual Behavior, Intention, Knowledge, Beliefs, Self-Efficacy Yes % No % 
Have you ever been in a clinical trial? (Q10) 9 45% 11 55% 
Have you ever asked your doctor or nurse about clinical trials? 
(Q9) 13 65% 7 35% 
If you were offered a clinical trial in the near future, would 
you\consider it? (Q11) 18 90% 2 10% 
Do you believe that health insurance covers standard-of-care 
costs in a clinical trial? (Q29) 14 70% 6 30% 
Do you think the ACA will be helpful in covering CT costs? (Q30) 11 55% 9 50% 
If your doctor or nurse mentions clinical trials, do you want to 
know more? (Q15) 18 90% 2 10% 
Do you think it makes sense to consider a clinical trial right after 
you are diagnosed with cancer? (Q18) 12 60% 8 40% 
Do you think clinical trials are an option to be considered only if 
other treatments stop working? (Q19) 7 35% 13 65% 
Table 4.33 continues on next page. 
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Table 4.33 (continued)	
Individual Behavior, Intention, Knowledge, Beliefs, Self-Efficacy 
(continued) Yes % No % 
Are you comfortable answering bringing up the subject of clinical 
trials to your doctor? (Q16) 19 95% 1 5% 
If a clinical trial required extra visits, would that stop you from 
participating? (Q23) 0 0% 20 100% 
If a clinical trial meant traveling an extra 30 miles each visit, 
would that stop you from participating? (Q24) 0 0% 20 100% 
Would your family be supportive if you were in a clinical trial? 
(Q25) 20 100% 0 0% 
 
 
Legend:  Teal = descriptive statistics  Purple = QCA results 
 
Figure 4.2. Translating Patients’ Findings to Opportunities within the Consolidated Framework 
for Implementation Research (CFIR) 
 
The next chapter discusses facilitators and barriers, and the challenges, strengths, and 
weaknesses associated with this study.  
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CHAPTER FIVE:  DISCUSSION AND CONCLUSIONS 
The Need for the Study 
This study was done because ovarian cancer will lead to 14,180 deaths and 21,290 new 
diagnoses in 2015 (ACS, 2015) and is the most lethal gynecologic cancer, with a 
disproportionately high ratio of deaths to initial diagnoses.  Ovarian cancer has had a relatively 
stable mortality rate since 1975 (NCI, 2013), despite a decrease in mortality for all gynecologic 
cancers combined. The disease is usually diagnosed at advanced stages, when, for most 
women, the disease will not be curable. Despite the existing National Comprehensive Cancer 
Network (NCCN) guideline that women with persistent or recurrent ovarian cancer should be 
offered a clinical trial as a treatment option along with the standard-of-care (SOC) regimen, few 
women with persistent or recurrent ovarian cancer are offered or enrolled in clinical trials. There 
were no studies on clinical trial barriers and facilitators that focused on women with ovarian 
cancer, thus indicating a need for a multiple case study to obtain information for this population. 
 Ovarian cancer compromises quality of life for women who are diagnosed with the 
disease, many of whom undergo initial and interval debulking surgery and multiple lines of 
cytotoxic chemotherapies that can cause adverse effects. Women who were employed may 
become disabled, and the impact of the disease will thus reverberate within the family, 
introducing the need for caregiving by family members. The disease burden includes health-
care costs, adding the expense of copays and significant costs associated with complex surgery 
and multiple regimens of chemotherapy. The average annual cost of care for an ovarian cancer 
patient, 65 or older, is $82,324 for initial treatment and $8,296 for continuing care; care in the 
last year of life, if death is the direct result of ovarian cancer, is projected to cost $99,715, 
versus $12,257 if death results from something other than ovarian cancer (Mariotto, Yabroff, 
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Feuer, & Brown, 2011). The standard of care can improve only via the clinical trial process, and 
yet the rarity of ovarian cancer makes adequate accrual numbers for statistical power difficult to 
achieve. It is thus especially important that regional, statewide, and national accrual-promoting 
network strategies be developed and shared to increase opportunities for women with advanced 
disease to enroll in clinical trials. 
Implications for Public Health 
The public health system includes “all public, private, and voluntary entities that 
contribute to the delivery of essential public health services within a jurisdiction (CDC, 2014).”  
This concept ensures that all entities’ contributions to the health and well-being of the 
community or state are recognized in assessing the provision of public health services. The 
three core functions of public health are assessment, policy development, and assurance, and 
the ten essential environmental health services align with the three core functions, as shown in 
the illustration below.  Within assessment, responsible entities should monitor health and diagnose  
Figure 5.1. The CDC’s 10 essential services within the 3 core functions of Public 
Health, obtained via http://www.cdc.gov/nphpsp/essentialservices.html (CDC, 2014). 
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and investigate health problems. Policy development should ensure that people are informed, 
educated, and empowered, that responsible organizations mobilize community partnerships, 
develop policies and enforce laws.  Assurance must link people with providers of care in facilities 
staffed a competent workforce, for whom effectiveness, access, and quality are measurable, and is 
reinforced by research for new insights and innovative solutions (CDC, 2014). 
 Physicians who see women prior and up to their diagnosis may be unaware of the NCCN 
guideline that states a woman with recurrent or persistent ovarian cancer should be offered both the 
standard of care and/or a clinical trial. They all not to be blamed for lack of awareness; rather, the 
need for awareness of the NCCN guideline should be supported by continuing education resources.  
All providers and practices should be aware of the NCCN guideline and do their best to uphold it, 
even if they must refer the patient out of network to another practice or facility that has a suitable 
clinical trial.  
Initiatives should promote practice partnerships and referral networks that make information 
on and access to clinical trials more prevalent. A strategy that rewards referring physicians and 
encourages the patient’s return to the referring physician for care might stimulate more referrals to 
centers that offer clinical trials. Assurance that women with recurrent or advanced ovarian cancer 
are offered, per the NCCN guideline, either the standard of or a clinical trial can be realized only 
through the provision of multidisciplinary provider education that is delivered with regularity to all 
members of the practice team. 
Implications for Practice 
Women with Ovarian Cancer  
The Tampa Bay area has Florida’s only NCI-designated comprehensive cancer center, 
Moffitt Cancer Center; in addition there are other hospitals within the Florida Cancer Specialist 
network that offer clinical trials.  Despite having some of the best resources in the Tampa Bay 
area, there are knowledge deficits and misperceptions in practice and among patients that 
interfere with adherence to the NCCN guideline for women with persistent or recurrent ovarian 
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cancer. Women in rural regions of Florida presumably not only have misperceptions, but also 
limited access as shown in Figure 2.4 in Chapter 2. Figure 2.4 indicated that as of 2013/14, 
there were only 13 gynecologic oncologists in the upper third of Florida, compared to 33 in 
central Florida and 39 in the southern third of the state.  
The NCCN guideline should be shared more prominently in the public arena, enabling a 
woman with recurrent or advanced ovarian cancer to ask her oncologist if she or he can offer or 
help find a clinical trial, enabling her to make an informed decision about whether to pursue a 
study or the standard of care.  Women need tools for proactive discussions with oncologists and 
skills to increase comfort in asking about options and the rationale for decisions about care. 
Tools might include web-based trial-matching tools, sample lists of questions to ask physicians, 
and how to have dialog that results in substantive replies over a simple yes or no. 
Oncology Practices 
There is a need for education for all disciplines within the practice:  physicians, physician 
assistants and nurse practitioners, and clinic nurses. Education should focus not only on 
knowledge of the NCCN guideline, but also on skills on how to discuss, refer, and help women 
find ovarian cancer clinical trials. Informing women on ovarian cancer clinical trials should not 
begin after treatment fails, but as early as possible after the diagnosis to enable them to take 
advantage of studies on biomarker-based agents, remission-sustaining agents, and studies 
exploring novel dosing regimens and/or drug combinations. Practices should have visible 
resources that can serve as cues for the patient to begin dialog about clinical trials. To stimulate 
referrals for clinical trials, it is critical to implement partnerships and strategies that reward 
referring oncologists, whether by sharing remuneration or some type of credit. The strategies 
should engage the referring physician in the patient’s status and/or progress during the trial, 
ideally by means of expedient shared electronic medical records. The principle investigator of 
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the clinical trial should encourage the patient to seek non-trial-related care from the referring 
physician.  
Discussion and Conclusions 
This multiple case study attempted to answer the following research questions: 
1. What necessary and/or sufficient factors, based on Qualitative Comparative 
Analysis (QCA)(Ragin, 1989), within the gynecologic oncology practice network 
in Florida, enable a woman with recurrent or persistent ovarian cancer to enroll in 
a clinical trial? 
2. What barriers and facilitators exist with regard to enrolling women with ovarian 
cancer in clinical trials? 
Women with Ovarian Cancer 
Research Question 1. This exploratory multiple case study looked at factors within the 
domains of the Consolidated Framework for Implementation Research (CFIR) associated within 
enrollment in clinical trials. Data was obtained from two populations: women with ovarian 
cancer, and nurses in gynecologic and medical oncology practices.  
There is no existing definitive clinical-trial enrollment process across cancer centers and 
oncology practices, some of which do not offer any ovarian cancer clinical trials. A definitive 
process between/among institutions might have made the search for sufficient conditions 
associated with enrollment in clinical trials less challenging. The focus of this exploratory 
multiple case study was thus was on necessary conditions. 
Despite multiple attempts to try numerous iterative factor combinations, the investigator 
was unable to achieve a perfect solution of 1.0 for coverage and 1.0 for consistency. The 
highest consistency (1.0) and coverage (0.83) for women who have been in clinical trials was 
that they were stage III/IV, wanted information, and engaged in discussion about clinical trials, 
making those factors necessary for enrollment in a study. The reason that coverage may not 
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have achieved 1.0 is that one of the patients had participated in arthritis clinical trials and may 
not have participated in an ovarian cancer treatment study, and she was not able to be reached 
by telephone for clarification. Another unique condition existed with a woman who said neither 
her nurse nor physician had suggested a trial, but she had participated in one; she thus may 
have proactively sought one on her own. With regard to intentions or willingness to consider a 
clinical trial, some women said they would not participate because they were currently in 
treatment, thus it was unclear whether they would pursue a clinical trial if they were not in 
treatment or were in treatment that failed to stabilize or diminish their cancer. 
Early stage patients who were cured of ovarian cancer were amenable to considering 
clinical trials, but no conclusion can be drawn for that small subset of three early stage (I/II) 
patients who consented to this study. Women with early and later stage ovarian cancer, 
however, all stated a desire for information on clinical trials, and all stated that their family 
members would support them if they participated in a clinical trial.  Women indicated that they 
hear about and discuss clinical trials mostly with their physician; for many physicians, however, 
including some who are affiliated with institutions that offer clinical trials, clinical studies are not 
a priority. Women are not always aware that recurrent cancer is terminal, or that the “gold 
standard” is not synonymous with a cure.  
Research Question 2. The data suggests that discussion with the provider of care, to 
some extent the existence of patient-accessible clinical trial literature in the practice, knowledge 
that health insurance covers standard of care costs, and the provider offering clinical trials are 
facilitators for participation. Absence of those factors thus constitutes a barrier. 
All women who participated in the study said they want more information about clinical 
trials and that their families would support them if they participated in trials. Barriers are thus the 
absence of discussion with providers, having a provider who does not offer on-site clinical trials, 
and not knowing that one’s medical coverage will pay for the standard-of-care costs in a clinical 
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trial, or that the Affordable Care Act stipulates that clinical trial costs must be covered. Women 
believe that trials should be a final option after treatment fails, which is a significant barrier to 
enrollment because they will likely fail to meet the inclusion criteria on number of prior 
treatments that are allowed. Travel and extra visits were not a barrier to any of the women who 
were surveyed. 
Practice Nurses 
Research Question 1. As previously explained, the small sample of nurses (7) was not 
conducive to yielding a combination of conditions with coverage and consistency of 1.0. The 
highest coverage and consistency were 0.8, for the impact of having a practice team plan 
related to enrolling women with ovarian cancer in clinical trials, resulting in nurses feeling 
informed and comfortable with questions women might ask about trials. Numerous combinations 
of conditions were tried, and nothing else resulted in coverage and consistency that exceeded 
0.75. 
Research Question 2. More clinical-trial enrolling-referring nurses have a practice team 
plan (67% versus 25%), suggesting that having a plan is a facilitator and not having one is a 
barrier. Additional facilitators are recognition that health insurance covers standard of care 
costs, and that the ACA supports clinical trial costs. While not quite reaching a 20% difference, 
the perception that clinical trials should be the last resort after the standard of care has failed is 
likely impeding eligibility because of limits on maximum prior regimens as well as having poor 
ECOG scores associated with complications of advanced disease. The belief that women 
should be informed about clinical trials as early as possible after diagnosis is a facilitator; 
absence of that belief is thus a barrier to enrollment. The fact that women bring up the 
discussion about clinical trials to enrollers may be related to the population that seeks care at 
facilities that offer clinical trials; regardless, it suggests that women would do well to ask the 
question, which, if no trials are offered on site, may result in a referral. Table 4.18 in Chapter 
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Four suggests that practice resources could be used to improve knowledge and comfort levels 
among all nurses. 
Additional barriers stated by at least one nurse are feeling uninformed and 
uncomfortable with questions, lacking resources for patients in the practice or nursing education 
focused on ovarian cancer clinical trials. Barriers in the inner setting are failing to refer women 
to sites with trials, and low levels of nurses initiating discussion about trials. Nurses, like 
patients, are not always aware that health insurance covers standard costs of care for trial 
participants, or that the Affordable Care Act stipulates that clinical trial costs must be covered. 
Some nurses fail to see the benefit of early education and pursuit of ovarian cancer clinical 
trials, believing they are a last resort after all treatments fail. The lack of trials having priority 
status, as well as no incentives for trial enrollment, is an additional practice barrier to enrollment. 
Challenges 
The original intention for this study was to find at least twenty unique referring practice 
sites and compare survey responses for the theoretical domains between the woman with 
ovarian cancer and the referring practice nurse. The TCC search yielded only twenty referring 
practices, and most of those practices were transformed in the last few years by industry 
dynamics that led to the purchase of multiple practice sites by Florida Hospitals. Thus 
independent practitioners became part of a large system in which physicians rotate to various 
sites within one hospital system. It was thus impossible to match patients with referring 
physicians and practice nurses. 
The low response rate for practice nurses was unanticipated. A meta-analysis by Cho 
and colleagues sought to clarify effective strategies for improving response, such as mode of 
data collection, incentives, and number of follow-up attempts, all of which were found to be 
significantly related to response rates of physicians and nurses. which have declined steadily 
between 1958 (about 80%) to 2012 (about 40%) ({{Cho, Johnson, & Vangeest, 2013). The Cho 
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team found that the online survey mode had the lowest rate of response (38%), compared to 
mailed surveys (57%) and mixed types (49%), the last referring to blending fax and email with 
mailing options for greater flexibility. The factors believed to diminish online survey response are 
mistrust of the internet and regulations by gatekeepers. Personalization was cited as another 
important element for improving response. 
For invitations to take the survey, only physician names, not the names of their nurses, 
were available, thus envelopes were addressed to the primary nurse for Dr. “Doe,” followed by 
the practice address. The lack of personalization likely left the decision to deliver the letter up to 
a gatekeeper, who may or may not have opened and delivered the letter. Lack of names greatly 
complicated follow-up contacts; telephone calls, for example, requested the name of the nurse 
for Dr. Doe, which brought the immediate response of Are you a patient? No, was my response, 
but I am a nurse who needs to speak to her about clinical information, which sometimes got me 
to the nurse’s voice mail, the next barrier, because nurses are extremely busy with patients. 
Honesty with a particular gatekeeper precipitated her statement that all surveys must be 
approved by the business office prior to being taken, and that the approval process would likely 
take months. The alternate plan, attempting to engage nurses through a nursing professor in the 
College of Nursing at the University of South Florida (USF) yielded three surveys. The next plan 
was to place an invitation to take the survey in the USF College of Nursing newsletter, which 
added one completed survey. 
Strengths and Limitations 
 
One strength of this study, on the patient side, is that the analysis focused only on women with 
ovarian cancer and their behaviors, intentions, knowledge, beliefs, and attitudes related to 
clinical trials, rather than on a blend of men and women with various cancers at various stages. 
A weakness, however, lies in the fact that most women were patients at Moffitt Cancer Center, 
where clinical research is part of the institution’s tripartite mission of combining clinical care, 
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academic medicine, and translational research. The women who are treated at Moffitt Cancer 
Center thus may be more aware of and informed about clinical research and may have a 
physician who is a principle investigator. It should be pointed out, however, that not all 
gynecologic oncologists at Moffitt Cancer Center are actively engaged in clinical trials.  
The original intention was to find 20 women with ovarian cancer who had been referred 
by 20 different practices, then survey a primary nurse for each of those practices. Chart reviews 
followed by a search for practice locations did not yield 20 unique referring sites, partly because 
some physicians had relocated and practice mergers under one large system had occurred, 
whereby that physician now rotated through multiple sites. The inclusion of both medical 
oncologists and gynecologic oncologists was necessary, however, because many women with 
ovarian cancer opt to have adjuvant chemotherapy close to home, administered by a medical 
oncologist. The low number of gynecologic oncologists compared to medical oncologists would 
have made it difficult or impossible to find 20 unique practices. The goal was to determine 
clinical trial enrollments and/or referrals in the 20 unique practices—that number of gynecologic 
oncology practices does not exist. Gynecologic oncologists perform surgery and adjuvant 
chemotherapy and generally have an assigned primary nurse; medical oncologists provide 
chemotherapy but not surgery, and they do not have one dedicated nurse, making it difficult to 
connect with medical oncology nurses without having a name. The lack of personalization, e.g., 
addressing the invitation letter to the “Primary Nurse of Doctor Doe,” likely had a lot to do with 
the low response rate for nurses. While it would have been possible to recruit more nurses from 
Moffitt Cancer Center, the purpose was to recruit nurses from external sites, and not have an 
imbalance or overrepresent a facility that does offer clinical trials and has made clinical research 
part of its culture. 
The Total Cancer Care (TCC) data request had a small yield, omitting a number of 
patients still living and with a history of care at Moffitt Cancer Center that exceeds three years, 
which is a question that the investigator, having no hands-on knowledge of how various data 
90	
	
bases are connected and manipulated, cannot answer. In the interest of protecting the privacy 
of those who have consented to provide and store biospecimens and clinical data via Moffitt’s 
TCC protocol, TCC, appropriately, is a “closed” system accessible only to honest brokers, thus 
the process of pulling and merging data is confidential.  Fortunately, there were several women 
known to the investigator through their participation in other studies, and they were contacted 
and agreed to participate in this study. 
The dichotomous survey data, indicating presence or absence of a condition of interest, 
led to why questions that could have best been clarified by follow-up interviews of women with 
ovarian cancer as well as nurses. With only seven nurses completing surveys, it may have been 
even more challenging to get them to agree to be interviewed. A subsequent study of this nature 
should definitely include interviews to better inform the researcher on other conditions that 
influenced the presence or absence of a condition. Interviews of nurses and patients would 
have helped clarify the discrepancy between nurses’ knowledge and support of sharing 
information about clinical trials early in the treatment continuum, and patients still embracing the 
notion that trials should be considered only as a last resort 
Recommendations 
Future studies should follow up the survey with interviews of the populations of interest to 
determine additional factors that influenced the presence or absence of a particular condition. 
Research should focus on nurses’ perceptions of the value of research in the practice setting as 
well as their knowledge, beliefs, and behaviors associated with cancer clinical trials. Nursing 
education should enlighten nurses on the types and dimensions of research, including practice 
patterns, behavioral, clinical, and translational science, and their value and contribution to 
improved quality, satisfaction, and outcomes.  This study could be applied to other cancers as 
well, whether they are rare or more common, and especially where there is a need to define 
barriers and facilitators to inform needed interventions to accelerate research.  A pilot 
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intervention that involves multiple institutions and is comprised of the following components 
within the Consolidated Framework for Implementation Research (CFIR) should be undertaken 
(see Figure 5.2). Information and education should target all levels of the framework. 
 
Legend:  Green = All findings combined 
Figure 5.2. Translating Findings into an Intervention as it Could Occur within the Consolidated 
Framework for Implementation Research (CFIR) 
 
Outer Setting 
Provider and patient knowledge deficits exist with regard to insurance coverage of stand-
of-care costs in clinical trials as well as ACA coverage requirements for clinical trial participants. 
Helpful trial-matching tools are available and underused, and practice networks need to be 
expanded by engaging larger numbers through the use of incentive-based partnerships.  In the 
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outer setting, multimedia education within each provider team member’s specialty organization 
could focus on deficits in awareness, knowledge, and interpersonal communication skills. 
Multimedia education could also be more fully integrated and made available to women with 
ovarian cancer through voluntary health agencies such as the Ovarian Cancer National Alliance 
and OCNA and the National Ovarian Cancer Coalition (NOCC), among others, as well as within 
provider environments. Circumvention of practice barriers may require more overt connections 
and education from pharmaceutical companies to lay consumers, raising awareness so that 
patients ask more questions and become more proactive seekers of cutting-edge therapies. 
Pharmaceutical connections with mass media and advocacy groups may accelerate enrollments 
and help solve the problem of trials limited by biomarker requirements or low incidence that are 
struggling to accrue adequate numbers of participants. Further, trial sponsors could create 
incentives, such as a referral fee, to encourage inter-institution collaboration to increase clinical 
trial enrollment. Non-monetary incentives might include benefits of partnerships that add an 
academic and/or research recognition component and the assurance that the patient will be 
referred back to the referring physician after the trial. 
Inner Setting 
All women with ovarian cancer expressed a desire for information on clinical trials, and 
all but one expressed that she is comfortable asking for information. Providers need to share 
information on clinical trials along with resources early in the treatment continuum, because 
many women, and some providers, are misinformed about waiting until the “gold standard” fails 
to consider clinical trials. Admittedly, changing practice culture is a huge undertaking that 
requires multidisciplinary and multi-institutional collaboration with partnerships and commitment 
at many levels. Determining the best ways to drive the change is an ambitious project that 
requires additional study and input from many leaders across industries and nonprofit settings. 
Networks must be created, resources shared, and technology amped up to bridge distance. 
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Compromise might involve infrequent travel by a patient to a central institution for baseline 
genomic testing and regulatory startup, with delivery of the intervention, surveillance, and data 
monitoring at a satellite site that shares data with the central institution. Today’s trials include 
biomarker-based agents as well as early trials to extend remission. Waiting until all treatments 
fail will reduce the likelihood of fulfilling eligibility criteria for number of prior treatments. Inner-
setting education in the practice setting for all providers and patients is needed in multiple 
formats such as dialog, print, and video. All practice participants need to be aware of the NCCN 
guideline that women with recurrent or advanced ovarian cancer should include the option of a 
clinical trial in addition to the standard of care.  
Process 
A protocol for a uniform pathway process, from diagnosis throughout the treatment 
continuum, needs to be created to guide providers in starting and sustaining informed patient-
centered dialog on ovarian cancer clinical trial opportunities, procedures, and resources. The 
process must employ metrics that measure provider adherence, patient satisfaction, adherence, 
and outcomes such as the number of enrollments and the impact of enrollment on longevity and 
quality of life.  
Adapted Intervention 
With no intervention, as the situation currently exists, enrollments are low and often 
nonexistent in un-networked practices that lack the necessary infrastructure for offering clinical 
trials. With a well-defined, protocol-driven process, fully engaged collaborative patient-centered 
practice networks, trial-referral incentives, retention of patients by referring physicians, and 
better informed nurses and patients, enrollment in ovarian cancer clinical trials would likely 
increase.  
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Conclusion 
This multiple case study, by surveying nurses and women with ovarian cancer, identified 
deficits within specific populations that interact with regularity for the purpose of ovarian cancer 
diagnostics, treatment, and quality of life management throughout the care continuum. The 
standard of care can improve only via the clinical trial process, and yet the rarity of ovarian 
cancer makes adequate accrual numbers for statistical power difficult to achieve. It is thus 
especially important that regional, statewide, and national accrual-promoting network strategies 
be developed and shared to increase opportunities for women with advanced disease to enroll 
in clinical trials. Clinical trials are an underutilized priority for improving the standard of care and 
reducing the high rate of morbidity and mortality associated with ovarian cancer. The data show 
deficits and needs within two key interrelated populations: medical oncology practice nurses and 
women with ovarian cancer.  Opportunities exist within each level of the Consolidated 
Framework for Implementation Research (CFIR); the findings can be related to each CFIR level 
to establish an interventional protocol to increase timely clinical trial enrollment by women with 
ovarian cancer. The next step is to pilot targeted interventions and disseminate findings. Results 
will be published in nursing and women’s health journals, and will be shared with appropriate 
advocacy groups, such as the Ovarian Cancer Research Foundation. The long-term goal is the 
establishment of a successful model for increased timely enrollment in ovarian cancer clinical 
trials, reduced morbidity and mortality, and improved quality of life.  
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